<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0206257519
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1997
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LUSTRAL 50MG TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        SERTRALINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        95.70
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SPIMACO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N06AB06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Lustral contains the active substance sertraline. Sertraline is one of a group of medicines called<br />Selective Serotonin Re-uptake Inhibitors (SSRIs); these medicines are used to treat depression and/or<br />anxiety disorders.<br />Lustral can be used to treat:<br />&bull; Depression and prevention of recurrence of depression (in adults).<br />&bull; Social anxiety disorder (in adults).<br />&bull; Post traumatic stress disorder (PTSD) (in adults).<br />&bull; Panic disorder (in adults).<br />&bull; Obsessive compulsive disorder (OCD) (in adults and children and adolescents aged 6-17 years<br />old).<br />Depression is a clinical illness with symptoms like feeling sad, unable to sleep properly or to enjoy life<br />as you used to.<br />OCD and Panic disorders are illnesses linked to anxiety with symptoms like being constantly troubled<br />by persistent ideas (obsessions) that make you carry out repetitive rituals (compulsions).<br />PTSD is a condition that can occur after a very emotionally traumatic experience, and has some<br />symptoms that are similar to depression and anxiety. Social anxiety disorder (social phobia) is an<br />illness linked to anxiety. It is characterised by feelings of intense anxiety or distress in social situations<br />(for example: talking to strangers, speaking in front of groups of people, eating or drinking in front of<br />others or worrying that you might behave in an embarrassing manner).<br />Your doctor has decided that this medicine is suitable for treating your illness.<br />You should ask your doctor if you are unsure why you have been given Lustral.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Lustral:</strong><br /> If you are allergic to sertraline or any of the other ingredients of this medicine (listed in section<br />6).<br /> If you are taking or have taken medicines called monoamine oxidase inhibitors (MAOIs such as<br />selegiline, moclobemide) or MAOI like drugs (such as linezolid). If you stop treatment with<br />sertraline, you must wait until at least one week before you start treatment with a MAOI. After<br />stopping treatment with a MAOI, you must wait at least 2 weeks before you can start treatment<br />with sertraline.<br /> If you are taking another medicine called pimozide (a medicine for mental disorders such as<br />psychosis).</p><p><strong>Warnings and precautions</strong><br />Talk to your doctor or pharmacist before taking Lustral.<br />Medicines are not always suitable for everyone. Tell your doctor before you take Lustral, if you suffer<br />from or have suffered in the past from any of the following conditions:<br /> If you have epilepsy (fit) or a history of seizures. If you have a fit (seizure), contact your doctor<br />immediately.<br /> If you have suffered from manic depressive illness (bipolar disorder) or schizophrenia. If you<br />have a manic episode, contact your doctor immediately.<br /> If you have or have previously had thoughts of harming or killing yourself (see below-Thoughts<br />of suicide and worsening of your depression or anxiety disorder).<br /> If you have Serotonin Syndrome. In rare cases this syndrome may occur when you are taking<br />certain medicines at the same time as sertraline. (For symptoms, see section 4. Possible Side<br />Effects). Your doctor will have told you whether you have suffered from this in the past.<br /> If you have low sodium level in your blood, since this can occur as a result of treatment with<br />Lustral. You should also tell your doctor if you are taking certain medicines for hypertension,<br />since these medicines may also alter the sodium level in your blood.<br /> If you are elderly as you may be more at risk of having low sodium level in your blood (see<br />above).<br /> If you have Liver disease; your doctor may decide that you should have a lower dose of Lustral.<br /> If you have Diabetes; your blood glucose levels may be altered due to Lustral and your diabetes<br />medicines may need to be adjusted.<br /> If you have a history of&nbsp;bleeding disorders (tendency to develop bruises), or if you<br />are pregnant (see Pregnancy, breast-feeding and fertility) or have been taking medicines which thin the<br />blood (e.g. acetylsalicyclic acid (aspirin), or warfarin) or may increase the risk of bleeding.<br /> If you are a child or adolescent under 18 years old. Lustral should only be used to treat children<br />and adolescents aged 6-17 years old, suffering from obsessive compulsive disorder (OCD). If<br />you are being treated for this disorder, your doctor will want to monitor you closely (see below<br />- Children and adolescents).<br /> If you are having electro-convulsive therapy (ECT).<br /> If you have eye problems, such as certain kinds of glaucoma (increased pressure in the eye).<br /> If you have been told that you have an abnormality of your heart tracing after an<br />electrocardiogram (ECG) known as prolonged QT interval.<br /> If you have heart disease, low potassium levels or low magnesium levels, family history of QT<br />prolongation, low heart rate and concomitant use of medications which prolong QT interval.</p><p><strong>Restlessness/Akathisia:</strong><br />The use of sertraline has been linked to a distressing restlessness and need to move, often being<br />unable to sit or stand still (akathisia). This is most likely to occur during the first few weeks of&nbsp;treatment. Increasing the dose may be harmful so if you develop such symptoms you should talk to<br />your doctor.</p><p><strong>Withdrawal reactions:</strong><br />Side effects relating to stopping treatment (withdrawal reactions) are common, particularly if the<br />treatment is stopped suddenly (see section 3 If you stop taking Lustral and section 4 Possible side<br />effects). The risk of withdrawal symptoms depends on the length of treatment, dosage, and the rate at<br />which the dose is reduced. Generally, such symptoms are mild to moderate. However, they can be<br />serious in some patients. They normally occur within the first few days after stopping treatment. In<br />general, such symptoms disappear on their own and wear off within 2 weeks. In some patients they<br />may last longer (2-3 months or more). When stopping treatment with sertraline it is recommended to<br />reduce the dose gradually over a period of several weeks or months, and you should always discuss<br />the best way of stopping treatment with your doctor.</p><p><strong>Thoughts of suicide and worsening of your depression or anxiety disorder:</strong><br />If you are depressed and/or have anxiety disorders you can sometimes have thoughts of harming or<br />killing yourself. These may be increased when first starting antidepressants, since these medicines all<br />take time to work, usually about two weeks but sometimes longer.<br /><strong>You may be more likely to think like this:</strong><br /> If you have previously had thoughts about killing or harming yourself.<br /> If you are a young adult. Information from clinical trials has shown an increased risk of suicidal<br />behaviour in adults aged less than 25 years with psychiatric conditions who were treated with<br />an antidepressant.<br />If you have thoughts of harming or killing yourself at any time, contact your doctor or go to a hospital<br />straight away.<br />You may find it helpful to tell a relative or close friend that you are depressed or have an anxiety<br />disorder, and ask them to read this leaflet. You might ask them to tell you if they think your<br />depression or anxiety is getting worse, or if they are worried about changes in your behaviour.<br />&nbsp;</p><p><strong>Sexual problems:</strong><br />Medicines like Lustral (so called SSRIs) may cause<br />symptoms of sexual dysfunction (see section 4). In some<br />cases, these symptoms have continued after stopping<br />treatment.</p><p><strong>Children and adolescents:</strong><br />Sertraline should not usually be used in children and adolescents less than 18 years old, except for<br />patients with Obsessive Compulsive Disorder (OCD). Patients under 18 have an increased risk of<br />undesirable effects, such as suicide attempt, thoughts of harming or killing themselves (suicidal<br />thoughts) and hostility (mainly aggressiveness, oppositional behaviour and anger) when they are<br />treated with this class of medicines. Nevertheless, it is possible that your doctor decides to prescribe<br />Lustral to a patient under 18 if it is in the patient&#39;s interest. If your doctor has prescribed Lustral to<br />you and you are less than 18 years old and you want to discuss this, please contact him/her.<br />Furthermore, if any of the symptoms listed above appear or worsen while you are taking Lustral, you<br />should inform your doctor. Also, the long-term safety of Lustral in regard to growth, maturation and<br />learning (cognitive) and behavioural development in this age group has not yet been demonstrated.</p><p><strong>Other medicines and Lustral:</strong><br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other<br />medicines.<br />Some medicines can affect the way Lustral works, or Lustral itself can reduce the effectiveness of<br />other medicines taken at the same time.</p><p>Taking Lustral together with the following medicines may cause serious side effects:<br /> Medicines called monoamine oxidase inhibitors (MAOIs), like moclobemide (to treat<br />depression) and selegiline (to treat Parkinson&rsquo;s disease), the antibiotic linezolid and methylene<br />blue (to treat high levels of methaemoglobin in the blood). Do not use Lustral together with<br />these medicines.<br /> Medicines to treat mental disorders such as psychosis (pimozide). Do not use Lustral together<br />with pimozide.<br />Talk to your doctor if you are taking the following medicines:<br />&bull; Medicines containing amphetamines (used to treat<br />attention deficit hyperactivity disorder (ADHD),<br />narcolepsy, and obesity).&bull; Herbal medicine containing St. John&rsquo;s Wort<br />(Hypericum perforatum). The effects of St. John&rsquo;s<br />Wort may last for 1-2 weeks.<br />&bull; Products containing the amino acid tryptophan.<br />&bull; Medicines to treat severe or chronic pain (opioids e.g.<br />tramadol, fentanyl).<br />&bull; Medicines used in anaesthesia (e.g. fentanyl,<br />mivacurium and suxamethonium).<br />&bull; Medicines to treat migraines (e.g. sumatriptan).<br />&bull; Blood thinning medicine (warfarin).<br />&bull; Medicines to treat pain/arthritis (e.g. metamizole,<br />Non steroidal antiinflammatory drug (NSAID) such<br />as ibuprofen, acetylsalicylic acid (aspirin)).<br />&bull; Sedatives (diazepam).<br />&bull; Diuretics (also called &lsquo;water&rsquo; tablets).<br />&bull; Medicines to treat epilepsy (phenytoin, phenobarbital,<br />carbamazepine).<br />&bull; Medicines to treat diabetes (tolbutamide).<br />&bull; Medicines to treat excessive stomach acid, ulcers and<br />heartburn (cimetidine, omeprazole, lanzoprazole,<br />pantoprazole, rabeprazole).<br />&bull; Medicines to treat mania and depression (lithium).<br />&bull; Other medicines to treat depression (such as<br />amitriptyline, nortriptyline, nefazodone, fluoxetine,<br />fluvoxamine).<br />&bull; Medicines to treat schizophrenia and other mental<br />disorders (such as perphenazine, levomepromazine<br />and olanzapine).<br />&bull; Medicines used to treat high blood pressure, chest<br />pain or regulate the rate and rhythm of the heart (such<br />as verapamil, diltiazem, flecainide, propafenone).<br />&bull; Medicines used to treat bacterial infections (such as<br />rifampicin, clarithromycin, telithromycin,<br />erythromycin).<br />&bull; Medicines used to treat fungal infections (such as<br />ketoconazole, itraconazole, posaconazole,<br />voriconazole, fluconazole).<br />&bull; Medicines used to treat HIV/AIDS and Hepatitis C<br />(protease inhibitors such as ritonavir, telaprevir).<br />&bull; Medicines used to prevent nausea and vomiting after<br />an operation or chemotherapy (aprepitant).<br />&bull; Medicines known to increase the risk of changes in<br />the electrical activity of the heart (e.g. some<br />antipsychotics and antibiotics).</p><p><strong>Lustral with food, drink and alcohol:</strong><br />Lustral tablets can be taken with or without food.<br />Alcohol should be avoided whilst taking Lustral.<br />Sertraline should not be taken in combination with grapefruit juice, as this may increase the level of<br />sertraline in your body.</p><p><strong>Pregnancy, breast-feeding and fertility:</strong><br />If you are pregnant or breast-feeding, think you may be<br />pregnant or are planning to have a baby, ask your doctor or<br />pharmacist for advice before taking this medicine.<br />The safety of sertraline has not fully been established in<br />pregnant women. Sertraline will only be given to you when<br />pregnant if your doctor considers that the benefit for you is<br />greater than any possible risk to the developing baby.<br />If you take Lustral near the end of your pregnancy there may<br />be an increased risk of heavy vaginal bleeding shortly after<br />birth, especially if you have a history of bleeding disorders.<br />Your doctor or should be aware that you are taking Lustral,<br />so they can advise you. When taken during pregnancy,<br />particularly in the last 3 months of pregnancy, medicines like<br />Lustral may increase the risk of a serious condition in babies,<br />called persistent pulmonary hypertension of the newborn<br />(PPHN), making the baby breathe faster and appear bluish.<br />These symptoms usually begin during the first 24 hours after<br />the baby is born. If this happens to your baby you should<br />contact your midwife and/or doctor immediately.<br />Your newborn baby might also have other conditions, which usually begin during the first 24 hours<br />after birth. Symptoms include:<br /> trouble with breathing,<br /> a blueish skin or being too hot or cold,<br /> blue lips,<br /> vomiting or not feeding properly,<br /> being very tired, not able to sleep or crying a lot,<br /> stiff or floppy muscles,<br /> tremors, jitters or fits,<br /> increased reflex reactions,<br /> irritability,<br /> low blood sugar.<br />If your baby has any of these symptoms when it is born, or you are concerned about your baby&rsquo;s<br />health, contact your doctor or midwife who will be able to advise you.<br />There is evidence that sertraline passes into human breast milk. Sertraline should only be used in<br />women during breast-feeding, if your doctor considers that the benefit exceeds any possible risk to the<br />baby.<br />Some medicines like sertraline may reduce the quality of sperm in animal studies. Theoretically, this<br />could affect fertility, but impact on human fertility has not been observed as yet.</p><p><strong>Driving and using machines:</strong><br />Psychotropic drugs such as sertraline may influence your ability to drive or use machines. You should<br />therefore not drive or operate machinery, until you know how this medication affects your ability to<br />perform these activities.</p><p>Lustral contains sodium<br />Lustral 50 mg film-coated tablets contain less than 1 mmol (23 mg) of sodium per tablet, i.e. they are<br />essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you.<br />Check with your doctor or pharmacist if you are not sure.<br />The recommended dose is:<br />Adults:<br />Depression and Obssessive Compulsive Disorder&nbsp;</p><p>For depression and OCD, the usual effective dose is 50 mg/day. The daily dose may be<br />increased in 50 mg increments and at intervals of at least one week over a period of weeks. The<br />maximum recommended dose is 200 mg/day.<br />Panic disorder, Social anxiety disorder and Post Traumatic Stress Disorder:<br />For panic disorder, social anxiety disorder and post traumatic stress disorder, treatment should<br />be started at 25mg/day, and increased to 50 mg/day after one week.<br />The daily dose then may be increased in 50 mg increments over a period of weeks. The<br />maximum recommended dose is 200 mg/day.<br />Use in children and adolescents:<br />Lustral must only be used to treat children and adolescents suffering from OCD aged 6-17 years old.<br />Obsessive Compulsive Disorder:<br />Children aged 6 to 12: the recommended starting dose is 25 mg daily.<br />After one week, your doctor may increase this to 50 mg daily. The maximum dose is 200 mg<br />daily.<br />Adolescents aged 13 to 17: the recommended starting dose is 50 mg daily.<br />The maximum dose is 200 mg daily.<br />If you have liver or kidney problems, please tell your doctor and follow the doctor&rsquo;s instructions.<br />Method of administration:<br />Lustral tablets may be taken with or without food.<br />Take your medication once daily either in the morning or evening.<br />Your doctor will advise you on how long to take this medication for. This will depend on the nature of<br />your illness and how well you are responding to the treatment. It may take several weeks before your<br />symptoms begin to improve. Treatment of depression should usually continue for 6 months after<br />improvement.</p><p>If you take more Lustral than you should:<br />If you accidentally take too much Lustral contact your doctor at once or go to the nearest hospital<br />casualty department. Always take the labelled medicine package with you, whether there is any<br />medication left or not.<br />Symptoms of overdose may include drowsiness, nausea and vomiting, rapid heartrate, shaking,<br />agitation, dizziness and in rare cases unconsciousness.<br />If you forget to take Lustral:<br />Do not take a double dose to make up for a forgotten dose. If you forget to take a dose, do not take the<br />missed dose. Just take the next dose at the right time.<br />If you stop taking Lustral:<br />Do not stop taking Lustral unless your doctor tells you to. Your doctor will want to gradually reduce<br />your dose of Lustral over several weeks, before you finally stop taking this medicine. If you suddenly<br />stop taking this medicine you may experience side effects such as dizziness, numbness, sleep<br />disturbances, agitation or anxiety, headaches, feeling sick, being sick and shaking. If you experience<br />any of these side effects, or any other side effects whilst stopping taking Lustral, please speak to your<br />doctor.<br />If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />Nausea is the most common side effect. The side effects depend on the dose and often disappear or<br />lessen with continued treatment.<br />&nbsp;</p><p><strong>Tell your doctor immediately:</strong><br />If you experience any of the following symptoms after taking this medicine, these symptoms can be<br />serious.<br />&bull; If you develop a severe skin rash that causes blistering (erythema multiforme), (this can affect<br />the mouth and tongue). These may be signs of a condition known as Stevens Johnson<br />Syndrome, or Toxic Epidermal Necrolysis (TEN). Your doctor will stop your treatment in these<br />cases.<br />&bull; Allergic reaction or allergy, which may include symptoms such as an itchy skin rash, breathing<br />problems, wheezing, swollen eyelids, face or lips.<br />&bull; If you experience agitation, confusion, diarrhoea, high temperature and blood pressure,<br />excessive sweating and rapid heartbeat. These are symptoms of Serotonin Syndrome. In rare<br />cases this syndrome may occur when you are taking certain medicines at the same time as<br />sertraline. Your doctor may wish to stop your treatment.<br />&bull; If you develop yellow skin and eyes which may mean liver damage.<br />&bull; If you experience depressive symptoms with ideas of harming or killing yourself (suicidal<br />thoughts).<br />&bull; If you start to get feelings of restlessness and are not able to sit or stand still after you start to<br />take Lustral. You should tell your doctor if you start to feel restless.<br />&bull; If you have a fit (seizure).<br />&bull; If you have a manic episode (see section 2 &ldquo;Warnings and precautions&rdquo;).<br />The following side effects were seen in clinical trials in adults<br />and after marketing.<br />Very common (may affect more than 1 in 10 people):<br />Insomnia, dizziness, sleepiness, headache, diarrhoea, feeling<br />sick, dry mouth, ejaculation failure, fatigue.<br />Common (may affect up to 1 in 10 people):<br />&bull; chest cold, sore throat, runny nose,<br />&bull; decreased appetite, increased appetite,<br />&bull; anxiety, depression, agitation, decreased sexual<br />interest, nervousness, feeling strange, nightmare,<br />teeth grinding,<br />&bull; shaking, muscular movement problems (such as<br />moving a lot, tense muscles, difficulty walking and<br />stiffness, spasms and involuntary movements of<br />muscles)*, numbness and tingling, muscle tense, lack<br />of attention, abnormal taste,<br />&bull; visual disturbance,<br />&bull; ringing in ears,<br />&bull; palpitations,<br />&bull; hot flush,<br />&bull; yawning,<br />&bull; upset stomach, constipation, abdominal pain,<br />vomiting, gas,<br />&bull; increased sweating, rash,<br />&bull; back pain, joint pain, muscle pain,<br />&bull; menstrual irregularities, erectile dysfunction,<br />&bull; malaise, chest pain, weakness, fever,<br />&bull; weight increased,<br />&bull; injury.<br />Uncommon (may affect up to 1 in 100 people):<br />&bull; gastroenteritis, ear infection,<br />&bull; tumour,<br />&bull; hypersensitivity, seasonal allergy,<br />&bull; low thyroid hormones,</p><p>&bull; suicidal thoughts, suicidal behaviour*, psychotic<br />disorder, thinking abnormal, lack of caring,<br />hallucination, aggression, euphoric mood, paranoia,<br />&bull; amnesia, decreased feeling, involuntary muscle<br />contractions, passing out, moving a lot, migraine,<br />convulsion, dizziness while standing up, abnormal<br />coordination, speech disorder,<br />&bull; enlarged pupils,<br />&bull; ear pain,<br />&bull; fast heartbeat, heart problem,<br />&bull; bleeding problems (such as stomach bleeding)*, high<br />blood pressure, flushing, blood in urine,<br />&bull; shortness of breath, nose bleed, breathing difficulty,<br />possible wheezing,<br />&bull; tarry stools, tooth disorder, inflammation of the<br />oesophagus, tongue problem, haemorrhoids,<br />increased saliva, difficulty swallowing, burping,<br />tongue disorder,<br />&bull; eye swelling, hives, hair loss, itching, purple spots on<br />skin, skin problem with blisters, dry skin, face<br />oedema, cold sweat,<br />&bull; osteoarthritis, muscle twitching, muscle cramps*,<br />muscular weakness,<br />&bull; increase in frequency of urination, problem urinating<br />unable to urinate, urinary incontinence, increase in<br />urination, nighttime urination,<br />&bull; sexual dysfunction, excessive vaginal bleeding,<br />vaginal haemorrhage, female sexual dysfunction,<br />&bull; swelling in legs, chills, difficulty walking, thirst,<br />&bull; increase in liver enzyme levels, weight decreased.<br />&bull; Cases of suicidal ideation and suicidal behaviours<br />have been reported during sertraline therapy or<br />early after treatment discontinuation (see section<br />2).<br />Rare (may affect up to 1 in 1,000 people):<br />&bull; abundant vaginal bleeding shortly after birth<br />(postpartum haemorrhage), see Pregnancy, breastfeeding<br />and fertility in section 2, for further<br />information*)<br />&bull; diverticulitis, swollen lymph glands, decrease in<br />clotting cells*, decrease in white blood cells*,<br />&bull; severe allergic reaction,<br />&bull; endocrine problems*,<br />&bull; high cholesterol, problems controlling blood sugar<br />levels (diabetes), low blood sugar, increase in blood<br />sugar levels*, low blood salt*,</p><p>&bull; physical symptoms due to stress or emotions,<br />terrifying abnormal dreams*, drug dependence, sleep<br />walking, premature ejaculation,<br />&bull; coma, abnormal movements, difficulty moving,<br />increased sensation, sudden severe headache (which<br />may be a sign of a serious condition known as<br />Reversible Cerebral Vasoconstriction Syndrome<br />(RCVS))*, sensory disturbance,<br />&bull; spots in front of eyes, glaucoma, double vision, light<br />hurts eye, blood in the eye, unequal sized pupils*,<br />vision abnormal*, tear problem,<br />&bull; heart attack, light-headedness, fainting, or chest<br />discomfort which could be signs of changes in the<br />electrical activity (seen on electrocardiogram) or<br />abnormal rhythm of the heart*, slow heartbeat,<br />&bull; poor circulation of arms and legs,<br />&bull; breathing fast, progressive scarring of lung tissue<br />(Interstitial Lung Disease)*, closing up of throat,<br />difficulty talking, breathing slow, hiccups,<br />&bull; A form of lung disease where eosinophils (a form of<br />white blood cell) appear in the lung in increased<br />numbers (eosinophilic pneumonia).<br />&bull; mouth ulceration, pancreatitis*, blood in stool, tongue<br />ulceration, sore mouth,<br />&bull; problems with liver function, serious liver function<br />problems*, yellow skin and eyes (jaundice)*,<br />&bull; skin reaction to sun*, skin oedema*, hair texture<br />abnormal, skin odour abnormal, hair rash,<br />&bull; breakdown of muscle tissue*, bone disorder,<br />&bull; urinary hesitation, decreased urination,<br />&bull; breast discharge, dry vaginal area, genital discharge,<br />red painful penis and foreskin, breast enlargement*,<br />prolonged erection, hernia, drug tolerance decreased,<br />&bull; increase in blood cholesterol levels, abnormal<br />laboratory tests*, semen abnormal, problems with<br />clotting*,<br />&bull; relaxation of blood vessels procedure.<br />Not known frequency cannot be estimated from the available<br />data:<br />&bull; lockjaw*,<br />&bull; bedwetting*,<br />&bull; partial loss of vision,<br />&bull; inflammation of the colon (causing diarrhoea)*,<br />&bull; heavy vaginal bleeding shortly after birth (postpartum<br />haemorrhage), see Pregnancy, breast-feeding and<br />fertility in section 2 for more information*.<br />*Side effect reported after marketing.</p><p>Additional side effects in children and adolescents<br />In clinical trials with children and adolescents, the side effects<br />were generally similar to adults (see above). The most<br />common side effects in children and adolescents were<br />headache, insomnia, diarrhoea and feeling sick.<br />Symptoms that can occur when treatment is discontinued<br />If you suddenly stop taking this medicine you may experience<br />side effects such as dizziness, numbness, sleep disturbances,<br />agitation or anxiety, headaches, feeling sick, being sick and<br />shaking (see section 3 &ldquo;If you stop taking Lustral&rdquo;).<br />An increased risk of bone fractures has been observed in<br />patients taking this type of medicines.<br />Reporting of side effects<br />If you get any side effects, talk to your doctor or pharmacist.<br />This includes any possible side effects not listed in this<br />leaflet. By reporting side effects,you can help provide more<br />information on the safety of this medicine.<br />To report any side effect(s):<br />&nbsp;</p><p><strong>&bull; Saudi Arabia:</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td>The National Pharmacovigilance Centre (NPC):<br />SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa</td></tr></tbody></table><p>&nbsp;</p><p><strong>&bull; Other GCC States:</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><em>- Please contact the relevant competent authority.</em></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Do not use this medicine after the expiry date which is stated on the pack after EXP. The expiry<br />date refers to the last day of that month.<br />Shelf life: 24 months.</p><p>Store below 30&deg; C.<br />Do not throw any medicines via wastewater or household waste. Ask your pharmacist how to throw<br />away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Lustral contains<br />Lustral film-coated tablets:<br />Each film-coated tablet contains sertraline hydrochloride equivalent to 50 mg sertraline.<br />The other ingredients are:<br />calcium hydrogen phosphate dihydrate (E341), microcrystalline cellulose (E460),<br />hydroxypropylcellulose (E463), sodium starch glycollate, (Type A) (see section 2 &ldquo;Lustral contains<br />sodium&rdquo;),&nbsp;magnesium stearate (E572),<br />hypromellose 2910/3cP&nbsp;(E464), hypromellose 2910/5cP (E464), titanium dioxide (E171), macrogol<br />400 (E1521), macrogol 6000 (E1521) and polysorbate 80 (E433).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Lustral 50 mg film-coated tablets:
A white to off-white capsular shaped, film-coated tablets engraved with a “LTL-50” logo on one side
and the other side with the letters “SP” and numbers “133”.
Sertraline tablets are available in blister packs containing 30 tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>SPIMACO<br />Al-Qassim Pharmaceutical Plant, Saudi Arabia<br />Under licence from Viatris<br />Manufactured by<br />SPIMACO<br />Al-Qassim Pharmaceutical Plant, Saudi Arabia<br />Under licence from Viatris</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                December 2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي لوسترال على المادة الفعالة سيرترالين. ينتمي سيرترالين إلى مجموعة من الأدوية تسمى مثبطات استرداد السيروتونين الانتقائية<br />وتستخدم هذه الأدوية لعلاج الاكتئاب و/أو اضطرابات القلق. ،(SSRIs)<br />يمكن استخدام لوسترال لعلاج:<br />&bull; الاكتئاب ومنع تكرار الإصابة به )في البالغين(.<br />&bull; اضطراب القلق الاجتماعي )في البالغين(.<br />في البالغين(. ( )PTSD( &bull; اضطراب الكرب التالي للصدمة<br />&bull; اضطراب الهلع )في البالغين(.<br />١٧ عامًا( . - في البالغين والأطفال والمراهقين من سن ٦ ( )OCD( &bull; اضطراب الوسواس القهري<br />الاكتئاب هو مرض إكلينيكي تصحبه أعراض مثل الشعور بالحزن أو عدم القدرة على النوم جيدًا أو الاستمتاع بالحياة كما اعتدت.<br />اضطرابات الوسواس القهري والهلع هي أمراض مرتبطة بالقلق وتكون مصحوبة بأعراض مثل الشعور المستمر بالاضطراب بسبب أفكار ملحة<br />)الوساوس( تجعلك تمارس طقوسًا متكررة )الأفعال القهرية(.<br />اضطراب الكرب التالي للصدمة هو حالة يمكن أن تحدث بعد التعرض لتجربة صادمة للمشاعر بشدة، وتكون مصحوبة ببعض الأعراض<br />المشابهة للاكتئاب والقلق. يعتبر اضطراب القلق الاجتماعي )الرهاب الاجتماعي( مرضًا مرتبطًا بالقلق. يتميز هذا الاضطراب بالشعور بالقلق أو<br />الانزعاج الشديد في المواقف الاجتماعية )على سبيل المثال: التحدث مع غرباء أو التحدث أمام مجموعة من الناس أو تناول الأطعمة والمشروبات<br />أمام الآخرين أو القلق من أنك قد تتصرف بطريقة محرجة(.<br />وقد قرر طبيبك أن هذا الدواء مناسب لعلاج مرضك.<br />ينبغي علي ك أن تسأل طبيبك إذا كنت غير متأكد من سبب إعطائك للوسترال.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>موانع استعمال لوسترال:<br />.) &bull; إذا كنت مصابًا بالحساسية تجاه سيرترالين أو أي مكون آخر من مكونات هذا الدواء )المدرجة في القسم ٦<br />مثل سيليجيلين، وموكلوبيميد( أو عقاقير تشبه MAOIs( &bull; إذا كنت تتناول أو قد تناولت أدوية تسمى مثبطات أكسيداز أحادي الأمين<br />مثبطات أكسيداز أحادي الأمين )مثل لينيزوليد(. إذا قمت بإيقاف العلاج بسيرترالين، يجب أن تنتظر مرور أسبوع على الأقل قبل بدء<br />العلاج بأحد مثبطات أكسيداز أحادي الأمين. بعد إيقاف العلاج بأحد مثبطات أكسيداز أحادي الأمين، يجب أن تنتظر مرور أسبوعين على<br />الأقل قبل بدء العلاج بسيرترالين.<br />&bull; إذا كنت تتناول دواءً آخر يسمى بيموزيد )دواء للاضطرابات العقلية مثل الذهان(.<br />الاحتياطات عند استعمال لوسترال</p><p>تحدث إلى طبيبك أو الصيدلي قبل تناول لوسترال.<br />لا تكون الأدوية مناسبة دائمًا للجميع. أبلغ طبيبك قبل أن تتناول لوسترال، إذا كنت تعاني أو قد عانيت في الماضي من أي من الحالات التالية:<br />&bull; إذا كنت تعاني من الصرع )النوبات( أو إذا كان لديك تاريخ من الإصابة بالنوبات. إذا أُصبت بنوبة، فقم بالاتصال بطبيبك في الحال.<br />&bull; إذا كنت قد عانيت من مرض هوس اكتئابي )اضطراب ثنائي القطب( أو الفصام. إذا أُصبت بنوبة هوسية، فقم بالاتصال بطبيبك في<br />الحال.<br />&bull; إذا كانت تراودك أو سبق أن راودتك أفكار لإيذاء نفسك أو الانتحار )انظر أدناه - &quot;الأفكار الانتحارية وتدهور حالة الاكتئاب أو<br />اضطراب القلق لديك&quot;(.<br />&bull; إذا كنت مصابًا بمتلازمة السيروتونين. قد تحدث هذه المتلازمة في حالات نادرة عندما تتناول أدوية معينة في نفس الوقت مع سيرترالين.<br />)لمعرفة الأعراض، انظر القسم ٤. &quot;الآثار الجانبية المحتملة&quot;(. سيكون طبيبك قد قام بإبلاغك إذا كنت قد عانيت من هذا في الماضي.<br />&bull; إذا كنت تعاني من انخفاض مستوى الصوديوم في دمك، نظرًا لأن ذلك قد يحدث ذلك نتيجة للعلاج بلوسترال. ينبغي أيضًا أن تقوم بإبلاغ<br />طبيبك إذا كنت تتناول أدوية معينة لعلاج ارتفاع ضغط الدم، حيث أن هذه الأدوية أيضًا قد تغير من مستويات الصوديوم في دمك.<br />&bull; إذا كنت من المسنين، حيث قد تكون عرضة لخطر أكبر لانخفاض مستوى الصوديوم في دمك )انظر أعلاه(.<br />&bull; إذا كنت تعاني من مرض بالكبد، حيث قد يقرر طبيبك أنه ينبغي عليك تلقي جرعة أقل من لوسترال.<br />&bull; إذا كنت تعاني من السكري، حيث قد تتغير مستويات الجلوكوز في دمك بسبب لوسترال وقد يلزم تعديل أدوية السكري الخاصة بك.<br />&bull; إذا كان لديك تاريخ من الإصابة&nbsp;اضطرابات النزيف ) قابلية للإصابة بالكدمات(، أو إذا كن ت حاملًا )انظر الحمل<br />والرضاعة والخصوبة( أو كنت تتناول أدوية لتسييل الدم )مثل حمض أسيتيل ساليسيليك )أسبرين( أو وارفارين( أو أدوية قد تزيد من<br />خطر النزيف.<br />١٧ عامًا الذين يعانون من - &bull; إذا كنت طفلًا أو مراهقًا تحت ١٨ عامًا. ينبغي استخدام لوسترال فقط لعلاج الأطفال والمراهقين من سن ٦<br />إذا كنت خاضعًا للعلاج من هذا الاضطراب، فسيحتاج طبيبك إلى مراقبتك عن كثب )انظر أدناه .)OCD( اضطراب الوسواس القهري<br />- &quot;الأطفال والمراهقون&quot;(.<br />.)ECT( &bull; إذا كنت تخضع للمعالجة بالصدمات الكهربائية<br />&bull; إذا كنت تعاني من مشكلات في العين، مثل بعض أنواع الزرق )زيادة الضغط داخل العين(.<br />.QT يُعرف بإطالة فترة ،(ECG) &bull; إذا تم إخبارك بأنك تعاني من اختلال في ضربات قلبك بعد عمل رسم للقلب<br />&bull; إذا كنت مصابًا بمرض بالقلب، وانخفاض مستويات البوتاسيوم أو انخفاض مستويات المغنسيوم، ولديك تاريخ عائلي من إطالة فترة<br />.QT وانخفاض معدل ضربات القلب والاستخدام المتزامن لأدوية تطيل من فترة ،QT<br />الشعور بالتململ/عدم الاستقرار:<br />تم الربط بين استخدام سيرترالين وشعور مزعج بعدم الاستقرار والحاجة للحركة، وعدم القدرة عادةً على الجلوس أو الوقوف بثبات )التململ(.<br />يحدث ذلك على الأرجح خلال الأسابيع القليلة الأولى من العلاج. قد تتسبب زيادة الجرعة في إلحاق الضرر بك، لذلك ينبغي عليك التحدث إلى<br />طبيبك إذا ظهرت عليك مثل هذه الأعراض.<br />تفاعلات الانسحاب:<br />إن الآثار الجانبية المرتبطة بإيقاف العلاج )تفاعلات الانسحاب( شائعة الحدوث، خاصةً في حالة إيقاف العلاج فجأة )انظر القسم ٣ &quot;إذا توقفت عن<br />تناول لوسترال&quot; والقسم ٤ &quot;الآثار الجانبية المحتملة&quot;(. يعتمد خطر الإصابة بأعراض الانسحاب على طول مدة العلاج والجرعة والمعدل الذي يتم<br />به تقليل الجرعة. وبشكل عام، تكون مثل هذه الأعراض خفيفة إلى متوسطة الشدة. وعلى الرغم من ذلك، فقد تكون خطيرة لدى بعض المرضى.<br />وعادةً ما تحدث خلال الأيام القليلة الأولى من إيقاف العلاج. تختفي هذه الأعراض عامةً من تلقاء نفسها وتزول خلال أسبوعين. وقد تستمر هذه<br />٣ أشهر أو أكثر(. عند إيقاف العلاج بسيرترالين، يوصى بتقليل الجر عة تدريجيًا على فترة تمتد - الأعراض لفترة أطول لدى بعض المرضى ) ٢<br />لعدة أسابيع أو أشهر، وينبغي عليك دائمًا أن تناقش مع طبيبك أفضل الطرق لإيقاف العلاج.<br />الأفكار الانتحارية وتدهور حالة الاكتئاب أو اضطراب القلق لديك:<br />إذا كنت تعاني من الاكتئاب و/أو من اضطرابات قلق، فقد تراودك في بعض الأحيان أفكار لإيذاء نفسك أو الانتحار. وقد تزيد هذه الحالات إذا<br />كنت تتناول مضادات الاكتئاب لأول مرة، حيث تستغرق كل هذه الأدوية وقتًا كي يظهر مفعولها، عادةً حوالي أسبوعين ولكن أحيانًا تستغرق أكثر<br />من ذلك.<br />قد تزداد احتمالات أن تراودك مثل هذه الأفكار في الحالات التالية:<br />&bull; إذا كان سبق أن راودتك أفكار لإيذاء نفسك أو الانتحار من قبل.<br />&bull; إذا كنت بالغًا يافعًا. أظهرت البيانات من التجارب الإكلينيكية زيادة خطر السلوك الانتحاري في البالغين الأصغر من ٢٥ عامًا الذين<br />يعانون من حالات نفسية وتم علاجهم بأحد مضادات الاكتئاب.<br />إذا راودتك أفكار لإيذاء نفسك أو الانتحار في أي وقت، فقم بالاتصال بطبيبك أو توجه إلى المستشفى على الفور.<br />قد تجد أنه من المفيد إبلاغ أحد أقربائك أو أصدقائك المقربين بأنك تعاني من الاكتئاب أو من اضطراب قلق، واطلب منه قراءة هذه النشر ة. يمكنك<br />أن تطلب منه إبلاغك إذا كان يعتقد أن اكتئابك أو القلق الذي تعاني منه يسوء أو إذا كان قلقًا من حدوث تغيرات في سلوكك.</p><p><strong>المشكلات الجنسية :</strong><br />التي تسمى) قد تسبب الأدوية مثل لوسترال SSRIs) أعراض الخلل الوظيفي<br />الجنسي )انظر القسم 4 .(وفي بع ض الحالات تستمر هذه الأعراض بعد<br />.التوقف عن العلاج</p><p><br /><strong>الأطفال والمراهقون:</strong><br />ينبغي عدم استخدام سيرترالين في الحالات العادية مع الأطفال والمراهقين الأصغر من ١٨ عامًا، إلا مع المرضى الذين يعانون من<br />يكون المرضى الأصغر من ١٨ عامًا عرضة لخطر أكبر للإصابة بالآثار غير المرغوب .)OCD( اضطراب الوسواس القهري<br />فيها، مثل محاولة الانتحار وأفكار لإيذاء الذات أو الانتحار )الأفكار الانتحارية( والعدائية )بشكل أساسي العنف والسلوك المعارض<br />والغضب( عند علاجهم بهذه الفئة من الأدوية. وعلى الرغم من ذلك، فقد يقرر طبيبك أن يصف لوسترال لمريض أصغر من ١٨<br />عامًا إذا كان يعتقد أن ذلك يصب في مصلحته. إذا وصف لك طبيبك لوسترال وكنت أصغر من ١٨ عامًا وأردت مناقشة هذا الأمر<br />معه، يُرجى الاتصال به/بها. بالإضافة إلى ذلك، إذا ظهرت أيٌ من الأعراض المدرجة أعلاه أو إذا تفاقمت أثناء تناولك لوسترال،<br />ينبغي عليك إخبار طبيبك. كذ لك لم يتم إثبات السلامة طويلة الأمد للوسترال فيما يخص النمو والنضج والتطور التعلمي )المعرفي(<br />والسلوكي في هذه الفئة العمرية .</p><p><br /><strong>التداخلات الدوائية من أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية :</strong><br />أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى.<br />يمكن أن تؤثر بعض الأدوية على آلية عمل لوسترال، أو قد يقلل لوسترال نفسه من فعالية الأدوية الأخرى التي يتم تناولها بالتزامن معه.<br />قد تنتج عن تناول لوسترال بالتزامن مع الأدوية التالية آثارٌ جانبية خطيرة:<br />مثل موكلوبيميد )لعلاج الاكتئاب( وسيليجيلين )لعلاج مرض ،)MAOI( &bull; الأدوية المسماة بمثبطات أكسيداز أحادي الأمين<br />باركنسون( والمضاد الحيوي لينيزوليد و الميثيلين أزرق )لعلاج مستويات الميتهيموجلوبين المرتفعة في الدم(. لا تستخدم<br />لوسترال بالتزامن مع تلك الأدوية .<br />&bull; أدوية علاج الاضطربات العقلية مثل الذهان )بيموزيد(. لا تستخدم لوسترال بالتزامن مع بيموزيد.</p><p>تحدث مع طبيبك إذا كنت تتناول الأدوية التالية:</p><p>الأدوية التي تحتوي على الأمفيتامينات )التي تستخدم لعلاج اضطراب<br />نقص الانتباه وفرط النشاط (ADHD)، .(والخدار، والسمنة<br />&bull; الأدوية العشبية التي تحتوي على نبتة سانت جون ) هايبريكوم بير فوراتوم(. قد تمتد تأثيرات نبتة سانت جونز من أسبوع إلى أسبوعان.<br />&bull; المنتجات التي تحتوي على الحمض الأميني تريبتوفان .<br />&bull; أدوية علاج الآلام الشديدة أو الحادة )مثل المواد الأفيونية والترامادول والفينتانيل(.<br />&bull; الأدوية المستخدمة في التخدير&nbsp; )فينتانيل ، وميفاكوريوم، وسوكساميثونيوم(.<br />&bull; أدوية علاج حالات الصداع النصفي )مثل سوماتريبتان(.<br />&bull; الأدوية المُسي لة للدم )وارفارين(.<br />مثل إيبوبروفين وحمض الأسيتيل )NSAID( &bull; الأدوية المستخدمة لعلاج الألم/التهاب المفاصل&nbsp;مثل ميتاميزول )و مضادات الالتهاب غير الستيرويدية<br />ساليسيليك )أسبرين((.<br />&bull; المهدئات )ديازيبام(.<br />&bull; مدرات البول )المسماة أيضًا بأقراص &quot;الماء&quot;(.<br />&bull; الأدوية المستخدمة لعلاج الصرع )فنيتوين، فينوباربيتال، كاربامازيبين(.<br />&bull; أدوية علاج مرض السكري )تولبوتاميد(.<br />&bull; أدوية علاج حموضة المعدة الزائدة والقرح وحرقة فم المعدة )سيميتيدين، أوميبرازول، لانزوبرازول، بانتوبرازول، رابيبرازول(.<br />&bull; أدوية علاج الهوس والاكتئاب )الليثيوم(.<br />&bull; الأدوية الأخرى المُستخدمة لعلاج الاكتئاب )مثل أميتريبتيلين، نورتريبتيلين، نيفازودون، فلوكسيتين، فلوفوكسامين(.<br />&bull; أدوية علاج الفصام والاضطرابات العقلية الأخرى )مثل بيرفينازين وليفوميبرومازين وأولانزابين(.<br />&bull; الأدوية المستخدمة لعلاج ضغط الدم المرتفع أو ألم الصدر أو لتنظيم معدل ونظم ضربات القلب )مثل فيراباميل، ديلتيازم، فليكاينيد،<br />بروبافينون(.<br />&bull; الأدوية المُستخدمة لعلاج حالات العدوى البكتيرية )مثل ريفامبيسين، كلاريثروميسين، تيليثروميسين، إريثروميسين(.<br />&bull; الأدوية المُستخدمة لعلاج حالات العدوى الفطرية )مثل كيتوكونازول، إيتراكونازول، بوزاكونازول، فوريكونازول، فلوكونازول(.<br />مثبطات البروتياز مثل ريتونافير ( C الإيدز والتهاب الكبد الوبائي /)HIV( &bull; الأدوية المُستخدمة لعلاج فيروس نقص المناعة البشرية<br />وتيلابريفير(.<br />&bull; الأدوية المستخدمة لمنع الغثيان وا لقيء بعد الخضوع لجراحة أو للعلاج الكيميائي )أبريبيتانت(.<br />&bull; الأدوية التي يُعرف عنها أنها تزيد من خطر حدوث تغيرات في النشاط الكهربي للقلب )مثل بعض مضادات الذهان والمضادات الحيوية(.<br />تناول لوسترال مع الطعام والشراب:<br />يمكن تناول أقراص لوسترال مع الطعام أو بدونه.<br />ينبغي تجنب شرب الكحوليات أثناء تناول لوسترال.</p><p>ينبغي عدم تناول سيرترالين مع عصير الجريب فروت، حيث أنه قد يؤدي إلى زيادة مستوى سيرترالين في جسمك.</p><p><strong>الحمل والرضاعة والخصوبة:</strong><br />إذا كن ت حاملًا أو ترضعين رضاعة طبيعية، أو تعتقدين أنك ربما تكونين حاملًا<br />.أو تخططين للحمل، فاستشيري طبيبك أو الصيدلي قب ل تناول هذا الدواء<br />لم يتم إثبات سلامة سيرترالين بشك ل كامل في السيدات الحوام ل .سيتم إعطاؤ ك<br />سيرترالين أثناء حملك فقط إذا رأى طبيب ك أن فوائده ل ك تفوق أي مخاط ر<br />..محتملة على الجنين<br />تتناولين لوسترال قبل نهاية الحمل، فقد يزيد خطر الإصابة بنزيف إذا ك ن ت<br />مهبلي حاد بعد الولادة بفترة وجيزة، خاصة إذ ا كان لديك تاريخ من<br />،الاضطرابات النزفية .يجب أن يكون طبيبك على علم بأن ك تتناولين لوسترال<br />،حتى يتمكن من تقديم النصح لك. عند تناول أدوي ة مثل لوسترال أثناء الحم ل<br />خاصة خلال الأشهر الثلاثة الأخير ة من الحمل، فقد تزيد هذه الأدوية من خط ر<br />حدو ث حالة مرضية خطيرة ف ي الأطفال، تسم ى ارتفاع ضغط الد م الرئو ي<br />المستمر في الأطفال حديثي الولادة (PPHN)، والذي يجعل الطفل يتنفس بشك ل<br />أسرع ويبدو لونه مائلًا للزرق ة .عادة ما يبدأ ظهور هذه الأعراض خلا ل<br />الساعات ال ٢٤ الأولى بعد ولادة الطفل .إذا حدث هذا لطفل ك فينبغي علي ك<br />.الاتصال بالقابلة الخاصة ب ك و/أو بطبيب ك على الفور</p><p><br />قد يُصاب طفل ك حديث الولادة أيضًا بحالات مرضية أخرى، عادةً ما تبدأ خلال الساعات ال ٢٤ الأولى بعد الولادة. وتتضمن الأعراض:<br />&bull; صعوبة في التنفس،<br />&bull; ازرقاق الجلد أو ارتفاع أو انخفاض شديد في درجة الحرارة،<br />&bull; ازرقاق الشفتين،<br />&bull; القيء أو عدم الرضاعة بشكل جيد،<br />&bull; التعب الشديد أو عدم القدرة على النوم أو كثرة البكاء،<br />&bull; تيبس أو لين العضلات،<br />&bull; الرعاش أو العصبية الشديدة أو النوبات،<br />&bull; زيادة ردود الأفعال المنعكسة،<br />&bull; التهيج،<br />&bull; انخفاض سكر الدم.<br />إذا ظهرت أي من هذه الأعراض على طفل ك بعد ولادته، أو إذا كن ت قلقة بشأن صحة طفل ك، فاتصلي بطبيب ك أو القابلة ، سيكون بوسعهما<br />نصيحتك.<br />هناك دلائل تؤكد مرور السيرترالين إلى لبن الثدي. ينبغي على النساء استخدام السيرترالين أثناء فترة الرضاعة فقط إذا رأى طبيب ك أن فوائده ل ك<br />تفوق مخاطره المحتملة على الطفل.<br />قد تقلل بعض الأدوية مثل السيرترالين من جودة الحيوانات المنوية في الدراسات على الحيوانات. نظريًا، قد يؤثر ذلك على الخصوبة، لكن لم تتم<br />ملاحظة التأثير على الخصوبة لدى البشر بعد.<br />تأثير لوسترال على القيادة واستخدام الآلات:<br />قد تؤثر الأدوية نفسية التأثير مثل سيرترالين على قدرتك على القيادة أو استخدام الآلات. لذا، ينبغي عليك عدم القيادة أو استخدام ا لآلات حتى<br />تعرف كيف تؤثر هذه الأدوية على قدرتك على أداء هذه النشاطات.</p><p>معلومات هامة حول بعض مكونات لوسترا ل<br />لوسترال يحتوي لوسترال على الصوديوم<br />تحتوي أقراص لوسترال ٥٠ ملجم المغلفة بطبقة رقيقة على أقل من ١ مليمول ) ٢٣ مجم( من الصوديوم لكل قرص، أي أنها تُعد<br />أساسًا &quot;خالية من الصوديوم&quot;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احرص دائمًا على تناول هذا الدواء تمامًا كما أخبرك طبيبك أو الصيدلي.<br />استشر طبيبك أو الصيدلي إذا لم تكن متأكدًا مما يجب عليك فعله.<br />الجرعة الموصى بها هي:<br />البالغون:<br />الاكتئاب واضطراب الوسواس القهري<br />تبلغ الجرعة الفعالة المعتادة لعلاج حالات الاكتئاب واضطراب الوسواس القهري ٥٠ ملجم/يوم. يمكن زيادة الجرعة اليومية بزيادات يبلغ<br />كل منها ٥٠ ملجم على فترات لا تقل عن أسبوع واحد على مدار فترة تمتد لأسابيع. ويكون الحد الأقصى للجرعة الموصى بها هو ٢٠٠<br />ملجم/اليوم.<br />اضطراب الهلع واضطراب القلق الاجتماعي واضطراب الكرب التالي للصدمة:</p><p>ينبغي بدء علاج اضطراب الهلع واضطراب القلق الاجتماعي واضطراب الكرب التالي للصدمة بجرعة تبلغ ٢٥ ملجم/يوم، وتزداد إلى<br />٥٠ ملجم/يوم بعد مرور أسبوع.<br />يمكن زيادة الجرعة بعدها على هيئة زيادات تبلغ ٥٠ ملجم على فترة تمتد لأسابيع. ويكون الحد الأقصى للجرعة الموصى بها هو ٢٠٠<br />ملجم/اليوم.<br />الاستخدام في الأطفال والمراهقين:<br />١٧ عامًا. - يجب أن يُستخدم لوسترال فقط لعلاج الأطفال والمراهقين الذين يعانون من اضطراب الوسواس القهري ويبلغون من العمر ٦<br />اضطراب الوسواس القهري:<br />الأطفال الذين تتراوح أعمارهم بين ٦ إلى ١٢ عامًا: تكون الجرعة المبدئية الموصى بها ٢٥ ملجم يوميًا.<br />بعد مرور أسبوع، قد يزيد طبيبك الجرعة لتصل إلى ٥٠ ملجم يوميًا. ويكون الحد الأقصى للجرعة هو ٢٠٠ ملجم/اليوم.<br />المراهقون الذين تتراوح أعمارهم بين ١٣ إلى ١٧ عامًا: تبلغ جرعة البدء الموصى بها ٥٠ ملجم يوميًا.<br />ويكون الحد الأقصى للجرعة هو ٢٠٠ ملجم/اليوم.<br />إذا كنت تعاني من مشكلات في الكبد أو الكلى، يرجى إخبار طبيبك واتباع تعليماته.<br />طريقة الاستعمال:<br />يمكن تناول أقراص لوسترال مع الطعام أو بدونه.<br />تناول الدواء مرة واحدة يوميًا في الصباح أو المساء.<br />سوف ينصحك طبيبك بالمدة التي ينبغي أن تواصل فيها تناول هذا الدواء. سيعتمد هذا على طبيعة المرض الذي تعاني منه ومدى استجابتك<br />للعلاج. قد يستغرق الأمر عدة أسابيع قبل أن تبدأ أعراضك في التحسن. ينبغي أن يستمر علاج الاكتئاب عادةً لمدة ٦ أشهر بعد التحسن.<br />الجرعة الزائدة من لوسترال:<br />إذا قمت بتناول جرعة زائدة من لوسترال عن طريق الخطأ، فاتصل بطبيبك فورًا أو اذهب إلى قسم الإصابات بأقرب مستشفى. أح ضر معك دائمًا<br />عبوة الدواء المزودة بملصق، حتى وإن لم يتبق بها شيء من الدواء.<br />قد تتضمن أعراض الجرعة المفرطة النعاس والغثيان والقيء وسرعة معدل نبضات القلب والارتجاف والهياج والدوار وفي بعض الحالات النادرة<br />فقدان الوعي.<br />نسيان تناول جرعة لوسترال:<br />لا تأخذ جرعة مضاعفة لتعويض جرعة منسية. في حالة نسيانك تناول إحدى الجرعات، فلا تتناول الجرعة الفائتة. قم فقط بتناول الجرعة التالية<br />في الموعد المعتاد.<br />التوقف عن تناول لوسترال:<br />لا تتوقف عن تناول لوسترال إلا إذا طلب منك طبيبك ذلك. سيرغب طبيبك في خفض جرعتك من لوسترال تدريجيًا على مدار عدة أسابيع قبل<br />توقفك نهائيًا عن تناول هذا الدواء. إذا توقفت عن تناول هذا الدواء بشكل مفاجئ فقد تتعرض للإصابة بآثار جانبية مثل الدوار، والشعور بالخدر ،<br />واضطرابات النوم، والتهيج أو القلق، والصداع، والشعور بالغثيان، والقيء، والارتجاف. إذا تعرضت لأيٍ من هذه الآثار الجانبية أو أي آثار<br />جانبية أخرى عند إيقاف تناولك للوسترال، يُرجى استشارة طبيبك.<br />إذا كان لديك المزيد من الأسئلة حول استخدام هذا المنتج، فاسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>كما هو الحال بالنسبة لجميع الأدوية، قد يسبب هذا الدواء آثارًا جانبية، غير أنها لا تصيب الجميع.<br />يُعد الغثيان الأثر الجانبي الأكثر شيوعًا. تعتمد الآثار الجانبية على الجرعة وغالبًا ما تختفي أو تقل مع استمرار العلاج.<br />احرص على إبلاغ طبيبك على الفور:<br />إذا أصبت بأيٍ من الأعراض التالية بعد تناول هذا الدواء، فقد تكون هذه الأعراض خطيرة.<br />&bull; إذا أُصبت بطفح جلدي شديد يسبب حدوث تقرحات )الاحمرار الجلدي عديد الأشكال(، )يمكن أن يؤثر هذا على الفم واللسان(. قد تكون<br />سيوقف طبيبك علاجك .)TEN( هذه علامات حالة تُعرف باسم متلازمة ستيفنز-جونسون أو تقشر الأنسجة المتموتة البشروية التسممي<br />في هذه الحالات.</p><p>&bull; تفاعل حساسية أو حساسية، والتي قد تتضمن أعراضًا مثل طفح جلدي مثير للحكة، ومشكلات في التنفس، وأزيز، وتورم في جفون<br />العينين أو الوجه أو الشفتين.<br />&bull; إذا أصبت بالتهيج، والتشوش، والإسهال، وارتفاع درجة الحرارة وضغط الدم، والعرق المفرط وتسارع ضربات القلب. هذه هي أعراض<br />متلازمة السيروتونين. قد تحدث هذه المتلازمة في حالات نادرة عندما تتناول أدوية معينة في نفس الوقت مع سيرترالين. قد يرغب<br />طبيبك في إيقاف علاجك.<br />&bull; إذا أصبت باصفرار الجلد والعينين والذي قد يعني تضرر الكبد.<br />&bull; إذا أصبت بأعراض اكتئابية مصحوبة بأفكار لإيذاء نفسك أو الانتحار )الأفكار الانتحارية(.<br />&bull; إذا بدأت في الشعور بعدم الاستقرار وعدم القدرة على الجلوس أو الوقوف بثبات بعد بدء تناول لوسترال. ينبغي عليك إبلاغ طبيبك إذا<br />بدأت في الشعور بعدم الاستقرار.<br />&bull; إذا أصبت بنوبة.<br />&bull; إذا أصبت بنوبة هوسية )انظر القسم ٢ &quot;تحذيرات واحتياطات&quot;(.</p><p>لوحظت الآثار الجانبية التالية في تجارب إكلينيكية على البالغين وبعد التسويق .</p><p><br />شائعة جدًا )قد تصيب أكثر من فرد واحد بين كل ١٠ أفراد(:<br />الأرق، الدوار، النعاس، الصداع، الإسهال، الشعور بالغثيان، جفاف الفم، عدم القدرة على القذف، الإرهاق.</p><p>&nbsp;</p><p>شائعة )قد تصيب ما يصل إلى فرد واحد بين كل ١٠ أفراد(:&bull; ،برد الصدر، احتقان الحلق، سيلان الأنف<br />&bull; ،القهم، زيادة الشهية<br />&bull; ،القلق، الاكتئاب، العصبية، انخفاض الرغبة الجنسية، التوتر<br />،الشعور بالغرابة، الكوابيس، الج ز على الأسنان<br />&bull; الارتجاف، مشكلات في حركة العضلات )مثل التحرك كثيرًا، توتر<br />العضلات، صعوبة المشي والتصلب، تشنج العضلات وتحركها<br />،بشكل لا إرادي*(، الخدر والتنميل، توتر العضلات، نقص الانتباه<br />،خلل التذوق<br />&bull; ،اضطراب الرؤية<br />&bull; ،طنين بالأذنين<br />&bull; ،خفقان<br />&bull; ،هبات حرارة<br />&bull; ،تثاؤب<br />&bull; ،اضطراب المعدة، الإمساك، ألم في البطن، القيء، الغازات<br />&bull; ،زيادة العرق، طفح جلدي<br />&bull; ،ألم بالظهر، ألم بالمفاصل، ألم بالعضلات<br />&bull; ،اضطرابات الحيض، خلل الانتصا ب<br />&bull; ،التوعك، ألم في الصدر، الضعف، الحمى<br />&bull; ،زيادة الوزن<br />&bull; التعرض لإصابا ت</p><p><br />غير شائعة )قد تصيب ما يصل إلى فرد واحد بين كل ١٠٠ فرد(:</p><p>&bull; ،التهاب المعدة والأمعاء، عدوى الأذن،الإصابة بأورام<br />&bull; ،فرط الحساسية، الحساسية الموسمي ة<br />&bull; ،انخفاض هرمونات الغدة الدرقية<br />&bull; أفكار انتحارية، سلوك انتحاري*، اضطراب ذهاني، تفكير غير<br />طبيعي، قلة الاهتمام، الهلوسة، العنف، مزاج مبتهج، جنون<br />،العظمة</p><p>&bull; ،فقدان الذاكرة، قلة الإحساس، انقباضات لا إرادية بالعضلات<br />فقدان الوعي، كثرة الحركة، الصدا ع النصفي، التشنجات، الدوار<br />،عند الوقوف، اعتلال التناسق، اضطراب الكلام<br />&bull; ،توسع البؤبؤ<br />&bull; ،ألم بالأذن<br />&bull; ،تسارع معدل ضربات القلب، مشكلات بالقلب<br />&bull; ،مشكلات النزيف )مثل نزيف المعد ة*(، ضغ ط الدم المرتفع<br />،اله بات، وجود دم في البول<br />&bull; ،ضيق التنفس، نزيف الأنف، صعوب ة التنفس، أزيز محتمل<br />&bull; البراز القطراني، اضطرا ب بالأسنان، التهاب بالمريء، مشكلة في<br />،اللسان، البواسير، زيادة اللعاب، صعوبة في البلع، التجشؤ<br />،،اضطراب اللسان<br />&bull; تورم العين، الشرى، تساق ط الشعر، الحكة، بقع أرجوانية على<br />،الجلد، مشكلة في الجلد مع ظهور بثور، جفا ف الجلد، تورم الوجه<br />،العرق البارد<br />&bull; التهاب المفاصل العظمي، انتفاض العضلات، تشنجات<br />،العضلات*، ضعف العضلات<br />&bull; ،زيادة معدل التبول، صعوبات التبول، عدم القدرة على التبول<br />،سلس بولي، زيادة في التبول، التبو ل أثناء الليل<br />&bull; ،خلل وظيفي جنسي، النزيف المهبل ي المفرط، النزيف المهبلي<br />،الخلل الوظيفي الجنس ي لدى الإناث<br />&bull; ،تورم بالساقين، القشعريرة، صعوبة في المشي، العطش<br />&bull; .زيادة مستويات إنزيمات الكبد، انخفاض الوزن</p><p>&bull; تم الإبلاغ عن حالات م ن الأفكار والسلوكيا ت الانتحارية خلال<br />العلاج بسيرترالين أ و بعد إيقاف العلاج به بفترة وجيزة )انظر<br />.(القسم ٢<br />نادرة)قد تصيب ما يصل إلى فرد واحد بين كل ١٠٠٠ فرد( :<br />&bull; ،نزيف مهبلي غزير بعد الولادة بفترة وجيزة )نزف ما بعد الولاد ة(<br />انظر &quot;الحمل والرضاعة والخصوبة &quot;في القسم ٢ لمعرفة المزيد)<br />(*من المعلومات<br />&bull; التهاب الرتج وتضخم الغدد الليمفاوي ة<br />&bull; ،*انخفاض في خلايا التجلط*، انخفاض في خلايا الدم البيضاء<br />&bull; ،رد فعل تحسسي شديد<br />&bull; ،*مشكلات الغدد الصما ء<br />&bull; ارتفاع نسبة الكوليسترول، مشكلا ت في التحكم في مستويات<br />،السكر في الدم )مرض السكر ي(، انخفاض نسبة السك ر في الدم<br />،*زيادة مستويات السكر في الدم*، انخفاض ملح الدم<br />&bull; أعراض جسدية بسبب التوتر أو الانفعالات، أحلام مرعبة غير<br />،طبيعية<br />&bull; ،إدمان العقاقير، المشي أثناء النوم، سرعة القذف<br />&bull; غيبوبة، حركات غير طبيعية، صعوبة في الحركة، زيادة<br />الإحساس، صداع شديد مفاجئ )قد يكون علامة على الإصابة<br />بحالة مرضي ة خطيرة معروفة باسم متلازمة تضيق أوعية المخ<br />القابلة للانعكاس (RCVS))*، ،اضطراب حسي</p><p>&bull; ،بقع أمام العينين، الزرق، ازدواجية الرؤية، ضوء يؤذي العينين<br />،*دم في العينين، عدم تساوي حجم البؤبؤين*، رؤية غير طبيعية<br />،مشكلة في الدموع<br />&bull; نوبة قلبية، دوخة خفيفة، أو الإغماء أو الشعور بعدم الراحة في<br />الصدر وهي ما يمكن أن تكون علامات على تغيرات في النشاط<br />،* الكهربائي )يظهر في رس م القل ب (أ و عدم انتظام ضربات القلب<br />،بطء ضربات القلب<br />&bull; .ضعف الدورة الدموية في الذراعين والساقين<br />&bull; التنفس بسرعة، تندب تدريجي لأنسجة الرئة )مرض الرئة<br />،الخلالي*(، إغلا ق الحلق، صعوب ة في التحدث، التنفس ببطء<br />،الفواق<br />&bull; شكل من أشكال أمراض الرئة حيث تظهر الأَيوزينيّات )شكل من<br />أشكال خلايا الدم البيضاء( في الرئة بأعداد متزايدة )الالتهاب الرئوي<br />اليوزيني(<br />&bull; ،تقرح الفم، التهاب البنكرياس*، دم في البراز، تقرح اللسان<br />،التهاب الفم<br />&bull; ،*مشكلات في وظائف الكبد، مشكلا ت خطيرة في وظائف الكبد<br />،*اصفرار الجلد والعينين )اليرقان(<br />&bull; ،رد فعل جلدي للشم س*، وذمة جلدية*، ملمس شعر غير طبيعي<br />،رائحة جل د غير طبيعية، طفح في الشعر<br />&bull; ،انهيار الأنسجة العضلية*، اضطراب العظام<br />&bull; ،احتباس البول، انخفاض التبول<br />&bull; إفرازات من الثدي، منطقة مهبلية جافة، إفرازا ت من الأعضاء<br />،*التناسلية، احمرار القضيب والقلفة بشكل مؤلم، تضخم الثدي<br />،الانتصاب لفترة طويلة<br />&bull; ،الفتاق، انخفاض مستوى تحمل الدواء<br />&bull; ارتفاع مستويات الكوليسترو ل في الدم، اختبارات مخبرية غير<br />،*طبيعية*، سائل منوي غير طبيعي، مشكلات في التخثر<br />&bull; .إجراءا ت إرخاء الأوعية الدموية<br />:غير معروف : لا يمكن تقدير معدل التكرار من البيانات المتاحة<br />&bull; ،*الكزاز<br />&bull; ،*التبول اللاإرادي<br />&bull; ،فقدان الرؤية بشكل جزئي<br />&bull; ،*التهاب القولون )يسب ب الإسها ل(<br />&bull; نزيف مهبلي حاد بعد الولادة بفترة وجيزة )نزيف ما بعد &bull;<br />الولادة(، انظري الحمل والرضاعة الطبيعية والخصوبة في القسم<br />.*لمزيد من المعلومات 2<br />.الآثار الجانبية التي تم الإبلاغ بها بعد التسويق*<br />آثار جانبية إضافية بين الأطفال والمراهقي ن<br />في التجار ب الإكلينيكية على الأطفال والمراهقين، كانت الآثار الجانبية عامة شبيهة بتلك التي تصيب البالغين )انظر أعلاه .(كانت الآثار الجانبية<br />الأكثر شيوعًا لدى الأطفال والبالغين الصداع والأرق والإسهال<br />.والغثيان<br />أعراض يمكن حدوثها عند توقف العلاج<br />إذا توقفت عن تناول هذا الدواء بشكل مفاجئ، فقد تتعرض للإصابة بآثار<br />جانبية مثل الدوار والشعور بالخدر واضطرابات النوم والتهيج أو</p><p>القلق والصداع والشعور بالغثيان والقيء والرعشة )انظر القسم ٣<br />.(&quot;إذا توقفت عن تناول لوسترال&quot;<br />لوحظت زيادة خطر التعرض لكسور العظام بين المرضى الذين يتناولون هذا<br />.النوع من الأدوية<br />الإبلا غ عن الأعرا ض الجانبي ة<br />إذا تعرضت لأي آثار جانبية، فتحدث إلى طبيبك أو الصيدلي .يشمل هذا أي<br />آثار جانبية محتملة وغير مدرجة ف ي هذه النشرة .بإبلاغك عن الآثار<br />الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول<br />.سلامة هذا الدوا ء<br />:للإبلاغ عن أي أثر جانبي )آثار جانبية(</p><p>&nbsp;</p><p><br /><strong>&bull; المملكة العربية السعودية:</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p>)NPC( المركز الوطني للتيقظ الدوائي<br />مركز الاتصال الموحد : ١۹۹۹۹<br />npc.drug@sfda.gov.sa : البريد الإلكتروني<br />https://ade.sfda.gov.sa : الموقع الإلكتروني</p></td></tr></tbody></table><p>&nbsp;</p><p><br /><strong>&bull; دول الخليج الأخرى :</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><em>-يرجى الاتصال بالسلطة المختصة ذات الصلة.</em></td></tr></tbody></table><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال .<br />يشير تاريخ انتهاء الصلاحية إلى .EXP لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على العبوة بعد<br />آخر يوم في ذلك الشهر .<br />صلاحية المستحضر: 36 شهر .<br />يُحفظ في درجة حرارة تقل عن ٣٠ درجة مئوية .<br />لا تتخلص من أي أدوية عبر مياه الصرف أو في المخلفات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها.<br />ستساعد هذه الإجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المكونات الأخرى هي:<br />،(E وهيدروكسي بروبيل السليلوز ( 463 ،(E وسليولوز مكروي بلوري ( 460 ،(E ثنائي هيدرات هيدروجين فوسفات الكالسيوم ( 341<br />2910/ ، وهيبروميلوز cP3&nbsp; (E وهيبروميلوز ( 464 )E وغليكولات نشا الصوديوم، )النوع أ(، )انظر القسم ٢ &quot;يحتوي لوسترال على الصوديوم&quot;( وستيارات المغنيسيوم ) 572<br />400 ، وماكروجول 6000 (E وماكروجول ( 1521 )E 2910/ ، وثاني أكسيد التيتانيوم ) 171 6 5cP (E464)<br />.)E433( وبوليسوربات 80 ،(E1521)</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right">أقراص لوسترال&nbsp;٥٠ ملجم المُغلفة بطبقة رقيقة:<br />والأرقام &quot;SP&quot; من جهة والجانب الآخر بالأحرف &quot;LTL- أقراص ذات لون أبيض إلى أبيض فاتح، كبسولة الشكل، مغلفة. محفورة بشعار &quot; 50<br />.&quot;133&quot;<br />تتوفر أقراص سيرترالين في عبوات شرائط دواء تحتوي على ٣٠ قرص .</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>صاحب رخصة التسوي ق<br />سبيماكو<br />مصنع الأدوية بالقصيم، المملكة العربية السعودي ة<br />بتصريح من شركة فياتري س<br />تم التصني ع بواسط ة<br />سبيماكو<br />مصنع الأدوية بالقصيم، المملكة العربية السعودي ة<br />بتصريح من شركة فياتري س</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ديسمبر ٢٠٢٣
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lustral 50 mg film coated tablets 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lustral 50 mg film-coated tablets:
Each film-coated tablet contains sertraline hydrochloride equivalent to 50 mg sertraline.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lustral film-coated tablets:
A white to off-white, capsular shaped, film-coated tablets engraved with a “LTL-50” logo on one side
and the other side with the letters “SP” and numbers “133”.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lustral is indicated for the treatment of:<br />Major depressive episodes. Prevention of recurrence of major depressive episodes.<br />Panic disorder, with or without agoraphobia.<br />Obsessive compulsive disorder (OCD) in adults and paediatric patients aged 6-17 years.<br />Social anxiety disorder.<br />Post traumatic stress disorder (PTSD).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p><br /><u><em>Initial treatment</em></u></p><p><br /><em>Depression and OCD</em></p><p>treatment should be started at a dose of 50 mg/day.</p><p><em>Panic Disorder, PTSD, and Social Anxiety Disorder</em><br />Therapy should be initiated at 25 mg/day. After one week, the dose should be increased to 50 mg once<br />daily. This dosage regimen has been shown to reduce the frequency of early treatment emergent side<br />effects characteristic of panic disorder.</p><p><u><em>Titration</em></u><br /><em>Depression, OCD, Panic Disorder, Social Anxiety Disorder and PTSD</em><br />Patients not responding to a 50 mg dose may benefit from dose increases. Dose changes should be<br />made in steps of 50 mg at intervals of at least one week, up to a maximum of 200 mg/day. Changes in<br />dose should not be made more frequently than once per week given the 24-hour elimination half life of<br />sertraline.<br />The onset of therapeutic effect may be seen within 7 days. However, longer periods are usually<br />necessary to demonstrate therapeutic response, especially in OCD.</p><p><u><em>Maintenance</em></u><br />Dosage during long-term therapy should be kept at the lowest effective level, with subsequent<br />adjustment depending on therapeutic response.</p><p><em>Depression</em><br />Longer-term treatment may also be appropriate for prevention of recurrence of major depressive<br />episodes (MDE). In most of the cases, the recommended dose in prevention of recurrence of MDE is<br />the same as the one used during current episode. Patients with depression should be treated for a<br />sufficient period of time of at least 6 months to ensure they are free from symptoms.</p><p><em>Panic disorder and OCD</em><br />Continued treatment in panic disorder and OCD should be evaluated regularly, as relapse prevention<br />has not been shown for these disorders.</p><p><em>Elderly patients</em><br />Elderly should be dosed carefully, as elderly may be more at risk for hyponatraemia (see section 4.4).</p><p><em>Patients with hepatic impairment</em><br />The use of sertraline&nbsp;in patients with hepatic disease should be approached with caution. A lower or less<br />frequent dose should be used in patients with hepatic impairment (see section 4.4). Sertraline&nbsp;should not<br />be used in cases of severe hepatic impairment as no clinical data are available (see section 4.4).</p><p><em>Patients with renal impairment</em><br />No dosage adjustment is necessary in patients with renal impairment (see section 4.4).</p><p><u><em>Paediatric population</em></u></p><p><br /><em>Children and adolescents with obsessive compulsive disorder</em></p><p>Age 13-17 years: Initially 50 mg once daily.<br />Age 6-12 years: Initially 25 mg once daily. The dosage may be increased to 50 mg once daily after one<br />week.<br />Subsequent doses may be increased in case of less than desired response in 50 mg increments over a<br />period of some weeks, as needed. The maximum dosage is 200 mg daily. However, the generally<br />lower body weights of children compared to those of adults should be taken into consideration when<br />increasing the dose from 50 mg. Dose changes should not occur at intervals of less than one week.<br />Efficacy is not shown in paediatric major depressive disorder.<br />No data is available for children under 6 years of age (see also section 4.4).</p><p><u>Method of administration</u><br />Sertraline&nbsp;should be administered once daily, either in the morning or evening.<br />Sertraline&nbsp;tablet can be administered with or without food.</p><p><em><u>Withdrawal symptoms seen on discontinuation of sertraline&nbsp;</u></em><br />Abrupt discontinuation should be avoided. When stopping treatment with sertraline&nbsp;the dose should be<br />gradually reduced over a period of at least one to two weeks in order to reduce the risk of withdrawal<br />reactions (see sections 4.4 and 4.8). If intolerable symptoms occur following a decrease in the dose or<br />upon discontinuation of treatment, then resuming the previously prescribed dose may be considered.<br />Subsequently, the physician may continue decreasing the dose, but at a more gradual rate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or any of the excipients listed in section 6.1.
Concomitant treatment with irreversible monoamine oxidase inhibitors (MAOIs) is contraindicated
due to the risk of serotonin syndrome with symptoms such as agitation, tremor and hyperthermia.
Sertraline must not be initiated for at least 14 days after discontinuation of treatment with an irreversible
MAOI. Sertraline must be discontinued for at least 7 days before starting treatment with an irreversible
MAOI (see section 4.5).
Concomitant intake of pimozide is contraindicated (see section 4.5).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Serotonin Syndrome (SS) or Neuroleptic Malignant Syndrome (NMS)</u><br />The development of potentially life-threatening syndromes like serotonin syndrome (SS) or<br />Neuroleptic Malignant Syndrome (NMS) has been reported with SSRIs, including treatment with<br />Lustral. The risk of SS or NMS with SSRIs is increased with concomitant use of other serotonergic<br />drugs (including other serotonergic antidepressants, amphetamines, triptans), with drugs which impair<br />metabolism of serotonin (including MAOIs e.g. methylene blue), antipsychotics and other dopamine<br />antagonists, and with opioids.&nbsp;Patients should be monitored for the emergence of signs and<br />symptoms of SS or NMS syndrome (see section 4.3).</p><p><u>Switching from Selective Serotonin Reuptake Inhibitors (SSRIs), antidepressants or antiobsessional<br />drugs</u><br />There is limited controlled experience regarding the optimal timing of switching from SSRIs,<br />antidepressants or antiobsessional drugs to Sertraline. Care and prudent medical judgment should be<br />exercised when switching, particularly from long-acting agents such as fluoxetine.</p><p><u>Other serotonergic drugs e.g. tryptophan, fenfluramine and 5-HT agonists</u><br />Co-administration of sertraline&nbsp;with other drugs which enhance the effects of serotonergic<br />neurotransmission such as&nbsp;amphetamines, tryptophan or fenfluramine or 5-HT agonists, or the herbal</p><p>medicine, St John&rsquo;s Wort (hypericum perforatum), should be undertaken with caution and avoided<br />whenever possible due to the potential for a pharmacodynamic interaction.</p><p><u>QTc Prolongation/Torsade de Pointes (TdP)</u><br />Cases of QTc prolongation and TdP have been reported during post-marketing use of sertraline&nbsp;. The<br />majority of reports occurred in patients with other risk factors for QTc prolongation/TdP. Effect on<br />QTc prolongation was confirmed in a thorough QTc study in healthy volunteers, with a statistically<br />significant positive exposure-response relationship. Therefore sertraline&nbsp;should be used with caution in<br />patients with additional risk factors for QTc prolongation such as cardiac disease, hypokalemia or<br />hypomagnesemia, familial history of QTc prolongation, bradycardia and concomitant use of<br />medications which prolong QTc interval (see sections 4.5 and 5.1).</p><p><u>Activation of hypomania or mania</u><br />Manic/hypomanic symptoms have been reported to emerge in a small proportion of patients treated<br />with marketed antidepressant and antiobsessional drugs, including sertraline. Therefore sertraline&nbsp;should<br />be used with caution in patients with a history of mania/hypomania. Close surveillance by the<br />physician is required. Sertraline&nbsp;should be discontinued in any patient entering a manic phase.</p><p><u>Schizophrenia</u><br />Psychotic symptoms might become aggravated in schizophrenic patients.</p><p><u>Seizures</u><br />Seizures may occur with sertraline&nbsp;therapy: sertraline&nbsp;should be avoided in patients with unstable epilepsy<br />and patients with controlled epilepsy should be carefully monitored. Sertraline&nbsp;should be discontinued in<br />any patient who develops seizures.</p><p><u>Suicide/suicidal thoughts/suicide attempts or clinical worsening</u><br />Depression is associated with an increased risk of suicidal thoughts, self harm and suicide (suiciderelated<br />events). This risk persists until significant remission occurs. As improvement may not occur<br />during the first few weeks or more of treatment, patients should be closely monitored until such<br />improvement occurs. It is general clinical experience that the risk of suicide may increase in the early<br />stages of recovery.<br />Other psychiatric conditions, for which sertraline&nbsp;is prescribed, can also be associated with an increased<br />risk of suicide-related events. In addition, these conditions may be co-morbid with major depressive<br />disorder. The same precautions observed when treating patients with major depressive disorder should<br />therefore be observed when treating patients with other psychiatric disorders.<br />Patients with a history of suicide-related events, or those exhibiting a significant degree of suicidal<br />ideation prior to commencement of treatment are known to be at greater risk of suicidal thoughts or<br />suicide attempts, and should receive careful monitoring during treatment. A meta-analysis of<br />placebo-controlled clinical trials of antidepressant drugs in adult patients with psychiatric disorders<br />showed an increased risk of suicidal behaviour with antidepressants compared to placebo in patients<br />less than 25 years old.<br />Close supervision of patients and in particular those at high risk should accompany drug therapy<br />especially in early treatment and following dose changes. Patients (and caregivers of patients) should<br />be alerted about the need to monitor for any clinical worsening, suicidal behaviour or thoughts and<br />unusual changes in behaviour and to seek medical advice immediately if these symptoms present.</p><p>Sexual dysfunction<br />Selective serotonin reuptake inhibitors (SSRIs) may cause symptoms of sexual<br />dysfunction (see section 4.8). There have been reports of long-lasting sexual<br />dysfunction where the symptoms have continued despite discontinuation of SSRIs.</p><p><br /><u>Paediatric population</u></p><p>Sertraline&nbsp;should not be used in the treatment of children and adolescents under the age of 18 years,<br />except for patients with obsessive compulsive disorder aged 6-17 years old. Suicide-related behaviours<br />(suicide attempt and suicidal thoughts), and hostility (predominantly aggression, oppositional<br />behaviour and anger) were more frequently observed in clinical trials among children and adolescents<br />treated with antidepressants compared to those treated with placebo. If, based on clinical need, a<br />decision to treat is nevertheless taken; the patient should be carefully monitored for appearance of<br />suicidal symptoms. In addition only limited clinical evidence is available concerning, long-term safety<br />data in children and adolescents including effects on growth, sexual maturation and cognitive and<br />behavioural developments A few cases of retarded growth and delayed puberty have been reported<br />post-marketing. The clinical relevance and causality are yet unclear (see section 5.3 for corresponding<br />preclinical safety data). Physicians must monitor paediatric patients on long term treatment for<br />abnormalities in growth and development.</p><p><u>Abnormal bleeding/Haemorrhage</u><br />There have been reports of bleeding abnormalities with SSRIs including cutaneous bleeding<br />(ecchymoses and purpura) and other haemorrhagic events such as gastrointestinal or gynaecological<br />bleeding, including fatal haemorrhages.<u>Selective serotonin reuptake inhibitors (</u>SSRIs/<u>)/serotonin-</u> <u>noradrenaline reuptake inhibitors (</u>SNRIs) may increase the risk of postpartum<br />haemorrhage (see sections 4.6, and 4.8). Caution is advised in patients taking SSRIs, particularly in<br />concomitant use with drugs known to affect platelet function (e.g. anticoagulants, atypical<br />antipsychotics and phenothiazines, most tricyclic antidepressants, acetylsalicylic acid and nonsteroidal<br />anti-inflammatory drugs (NSAIDs)) as well as in patients with a history of bleeding disorders<br />(see section 4.5).</p><p><u>Hyponatraemia</u><br />Hyponatraemia may occur as a result of treatment with SSRIs or SNRIs including sertraline. In many<br />cases, hyponatraemia appears to be the result of a syndrome of inappropriate antidiuretic hormone<br />secretion (SIADH). Cases of serum sodium levels lower than 110 mmol/L have been reported.<br />Elderly patients may be at greater risk of developing hyponatraemia with SSRIs and SNRIs. Also<br />patients taking diuretics or who are otherwise volume-depleted may be at greater risk (see Use in<br />elderly). Discontinuation of sertraline&nbsp;should be considered in patients with symptomatic hyponatraemia<br />and appropriate medical intervention should be instituted. Signs and symptoms of hyponatraemia<br />include headache, difficulty concentrating, memory impairment, confusion, weakness and<br />unsteadiness which may lead to falls. Signs and symptoms associated with more severe and/or acute<br />cases have included hallucination, syncope, seizure, coma, respiratory arrest, and death.</p><p><u>Withdrawal symptoms seen on discontinuation of sertraline&nbsp;</u><u>treatment</u><br />Withdrawal symptoms when treatment is discontinued are common, particularly if discontinuation is<br />abrupt (see section 4.8). In clinical trials, among patients treated with sertraline, the incidence of<br />reported withdrawal reactions was 23% in those discontinuing sertraline&nbsp;compared to 12% in those who<br />continued to receive sertraline&nbsp;treatment.<br />The risk of withdrawal symptoms may be dependent on several factors including the duration and dose<br />of therapy and the rate of dose reduction. Dizziness, sensory disturbances (including paraesthesia),<br />sleep disturbances (including insomnia and intense dreams), agitation or anxiety, nausea and/or<br />vomiting, tremor and headache are the most commonly reported reactions. Generally these symptoms<br />are mild to moderate; however, in some patients they may be severe in intensity. They usually occur<br />within the first few days of discontinuing treatment, but there have been very rare reports of such<br />symptoms in patients who have inadvertently missed a dose. Generally these symptoms are selflimiting<br />and usually resolve within 2 weeks, though in some individuals they may be prolonged (2-3<br />months or more). It is therefore advised that sertraline&nbsp;should be gradually tapered when discontinuing<br />treatment over a period of several weeks or months, according to the patient&rsquo;s needs (see section 4.2).</p><p><u>Akathisia/psychomotor restlessness</u></p><p>The use of sertraline&nbsp;has been associated with the development of akathisia, characterised by a<br />subjectively unpleasant or distressing restlessness and need to move often accompanied by an inability<br />to sit or stand still. This is most likely to occur within the first few weeks of treatment. In patients who<br />develop these symptoms, increasing the dose may be detrimental.</p><p><u>Hepatic impairment</u><br />Sertraline&nbsp;is extensively metabolised by the liver. A multiple dose pharmacokinetic study in subjects with<br />mild, stable cirrhosis demonstrated a prolonged elimination half life and approximately three-fold<br />greater AUC and Cmax in comparison to normal subjects. There were no significant differences in<br />plasma protein binding observed between the two groups. The use of sertraline&nbsp;in patients with hepatic<br />disease must be approached with caution. If sertraline&nbsp;is administered to patients with hepatic<br />impairment, a lower or less frequent dose should be considered. Sertraline&nbsp;should not be used in patients<br />with severe hepatic impairment (see section 4.2).</p><p><u>Renal impairment</u><br />Sertraline&nbsp;is extensively metabolised, and excretion of unchanged drug in urine is a minor route of<br />elimination. In studies of patients with mild to moderate renal impairment (creatinine clearance<br />30-60 ml/min) or moderate to severe renal impairment (creatinine clearance 10-29 ml/min), multipledose<br />pharmacokinetic parameters (AUC0-24 or Cmax) were not significantly different compared with<br />controls. Sertraline&nbsp;dosing does not have to be adjusted based on the degree of renal impairment.</p><p><u>Use in elderly</u><br />Over 700 elderly patients (&gt;65 years) have participated in clinical studies. The pattern and incidence<br />of adverse reactions in the elderly was similar to that in younger patients.<br />SSRIs or SNRIs including sertraline&nbsp;have however been associated with cases of clinically significant<br />hyponatraemia in elderly patients, who may be at greater risk for this adverse event (see<br />Hyponatraemia in section 4.4).</p><p><u>Diabetes</u><br />In patients with diabetes, treatment with an SSRI may alter glycaemic control. Insulin and/or oral<br />hypoglycaemic dosage may need to be adjusted.</p><p><u>Electroconvulsive therapy</u><br />There are no clinical studies establishing the risks or benefits of the combined use of ECT and sertraline.</p><p><u>Grapefruit juice</u><br />The administration of sertraline&nbsp;with grapefruit juice is not recommended (see section 4.5).</p><p><u>Interference with urine screening tests</u><br />False-positive urine immunoassay screening tests for benzodiazepines have been reported in patients<br />taking sertraline. This is due to lack of specificity of the screening tests. False-positive test results may<br />be expected for several days following discontinuation of sertraline&nbsp;therapy. Confirmatory tests, such as<br />gas chromatography/mass spectrometry, will distinguish sertraline&nbsp;from benzodiazepines.</p><p><u>Angle-Closure glaucoma</u><br />SSRIs including sertraline&nbsp;may have an effect on pupil size resulting in mydriasis. This mydriatic effect<br />has the potential to narrow the eye angle resulting in increased intraocular pressure and angle-closure<br />glaucoma, especially in patients pre-disposed. Sertraline&nbsp;should therefore be used with caution in<br />patients with angle-closure glaucoma or history of glaucoma.</p><p><u>Excipient information</u><br />This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say<br />essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Contraindicated </u></p><p><em><u>Monoamine Oxidase Inhibitors</u></em></p><p><em>Irreversible MAOIs (e.g. selegiline)</em></p><p>Sertraline&nbsp;must not be used in combination with irreversible MAOIs such as selegiline. Sertraline&nbsp;must not<br />be initiated for at least 14 days after discontinuation of treatment with an irreversible MAOI. Sertraline&nbsp;<br />must be discontinued for at least 7 days before starting treatment with an irreversible MAOI (see<br />section 4.3).</p><p><em>Reversible, selective MAO-A inhibitor (moclobemide)</em><br />Due to the risk of serotonin syndrome, the combination of sertraline&nbsp;with a reversible and selective<br />MAOI, such as moclobemide, should not be given. Following treatment with a reversible<br />MAO-inhibitor, a shorter withdrawal period than 14 days may be used before initiation of sertraline&nbsp;<br />treatment. It is recommended that sertraline&nbsp;should be discontinued for at least 7 days before starting<br />treatment with a reversible MAOI (see section 4.3).</p><p><em>Reversible, non-selective MAOI (linezolid)</em><br />The antibiotic linezolid is a weak reversible and non-selective MAOI and should not be given to<br />patients treated with Lustral (see section 4.3).<br />Severe adverse reactions have been reported in patients who have recently been discontinued from an<br />MAOI (e.g. methylene blue) and started on sertraline, or have recently had sertraline&nbsp;therapy discontinued<br />prior to initiation of an MAOI. These reactions have included tremor, myoclonus, diaphoresis, nausea,<br />vomiting, flushing, dizziness, and hyperthermia with features resembling neuroleptic malignant<br />syndrome, seizures, and death.</p><p><em><u>Pimozide</u></em><br />Increased pimozide levels of approximately 35% have been demonstrated in a study of a single low<br />dose pimozide (2 mg). These increased levels were not associated with any changes in EKG. While<br />the mechanism of this interaction is unknown, due to the narrow therapeutic index of pimozide,<br />concomitant administration of sertraline&nbsp;and pimozide is contraindicated (see section 4.3).</p><p><u>Co-administration with Lustral is not recommended</u><br />&nbsp;</p><p><em><u>CNS depressants and alcohol</u></em><br />The co-administration of sertraline&nbsp;200 mg daily did not potentiate the effects of alcohol, carbamazepine,<br />haloperidol, or phenytoin on cognitive and psychomotor performance in healthy subjects; however, the<br />concomitant use of sertraline&nbsp;and alcohol is not recommended.</p><p><em><u>Other serotonergic drugs</u></em><br />See section 4.4.<br />Caution is also advised with opioids [e.g. fentanyl (used in general anaesthesia or<br />in the treatment of chronic pain)], and other serotonergic drugs (including other<br />serotonergic antidepressants, amphetamines, triptans).</p><p><u>Special Precautions</u></p><p><em><u>Drugs that Prolong the QT Interval</u></em><br />The risk of QTc prolongation and/or ventricular arrhythmias (e.g. TdP) may be increased with<br />concomitant use of other drugs which prolong the QTc interval (e.g. some antipsychotics and<br />antibiotics) (see sections 4.4 and 5.1).</p><p><em><u>Lithium</u></em><br />In a placebo-controlled trial in normal volunteers, the co-administration of sertraline&nbsp;with lithium did not<br />significantly alter lithium pharmacokinetics, but did result in an increase in tremor relative to placebo,</p><p>indicating a possible pharmacodynamic interaction. When co-administering sertraline&nbsp;with lithium,<br />patients should be appropriately monitored.</p><p><em><u>Phenytoin</u></em><br />A placebo-controlled trial in normal volunteers suggests that chronic administration of sertraline&nbsp;<br />200 mg/day does not produce clinically important inhibition of phenytoin metabolism. Nonetheless, as<br />some case reports have emerged of high phenytoin exposure in patients using sertraline&nbsp;, it is<br />recommended that plasma phenytoin concentrations be monitored following initiation of sertraline&nbsp;<br />therapy, with appropriate adjustments to the phenytoin dose. In addition, co-administration of<br />phenytoin,&nbsp;a known CYP3A4 inducer, may cause a reduction of sertraline plasma levels.</p><p><em><u>Metamizole</u></em><br />Co-administration of sertraline with metamizole, which is an inducer of<br />metabolising enzymes including CYP2B6 and CYP3A4, may cause a reduction in<br />plasma concentrations of sertraline with potential decrease in clinical efficacy.<br />Therefore, caution is advised when metamizole and sertraline are administered<br />concurrently; clinical response and/or drug levels should be monitored as<br />appropriate.</p><p><em><u>Triptans</u></em><br />There have been rare post-marketing reports describing patients with weakness, hyperreflexia,<br />incoordination, confusion, anxiety and agitation following the use of sertraline&nbsp;and sumatriptan.<br />Symptoms of serotonergic syndrome may also occur with other products of the same class (triptans). If<br />concomitant treatment with sertraline&nbsp;and triptans is clinically warranted, appropriate observation of the<br />patient is advised (see section 4.4).</p><p><em><u>Warfarin</u></em><br />Co-administration of sertraline&nbsp;200 mg daily with warfarin resulted in a small but statistically significant<br />increase in prothrombin time, which may in some rare cases unbalance the INR value.<br />Accordingly, prothrombin time should be carefully monitored when sertraline&nbsp;therapy is initiated or<br />stopped.</p><p><u><em>Other drug interactions, digoxin, atenolol, cimetidine</em></u><br />Co-administration with cimetidine caused a substantial decrease in sertraline&nbsp;clearance. The clinical<br />significance of these changes is unknown. Sertraline&nbsp;had no effect on the beta-adrenergic blocking ability<br />of atenolol. No interaction of sertraline&nbsp;200 mg daily was observed with digoxin.</p><p><em><u>Drugs affecting platelet function</u></em><br />The risk of bleeding may be increased when medicines acting on platelet function (e.g. NSAIDs,<br />acetylsalicylic acid and ticlopidine) or other medicines that might increase bleeding risk are<br />concomitantly administered with SSRIs, including sertraline&nbsp;(see section 4.4).</p><p><em><u>Neuromuscular Blockers</u></em><br />SSRIs may reduce plasma cholinesterase activity resulting in a prolongation of the neuromuscular<br />blocking action of mivacurium or other neuromuscular blockers.</p><p><em><u>Drugs Metabolized by Cytochrome P450</u></em><br />Sertraline&nbsp;may act as a mild-moderate inhibitor of CYP 2D6. Chronic dosing with sertraline&nbsp;50 mg daily<br />showed moderate elevation (mean 23%-37%) of steady-state desipramine plasma levels (a marker of<br />CYP 2D6 isozyme activity). Clinical relevant interactions may occur with other CYP 2D6 substrates<br />with a narrow therapeutic index like class 1C antiarrhythmics such as propafenone and flecainide,<br />TCAs and typical antipsychotics, especially at higher sertraline&nbsp;dose levels.<br />Sertraline&nbsp;does not act as an inhibitor of CYP 3A4, CYP 2C9, CYP 2C19, and CYP 1A2 to a clinically<br />significant degree. This has been confirmed by in-vivo interaction studies with CYP3A4 substrates<br />(endogenous cortisol, carbamazepine, terfenadine, alprazolam), CYP2C19 substrate diazepam, and<br />CYP2C9 substrates tolbutamide, glibenclamide and phenytoin. In vitro studies indicate that sertraline&nbsp;<br />has little or no potential to inhibit CYP 1A2.<br />Intake of three glasses of grapefruit juice daily increased the sertraline&nbsp;plasma levels by approximately<br />100% in a cross-over study in eight Japanese healthy subjects. Therefore, the intake of grapefruit juice<br />should be avoided during treatment with sertraline&nbsp;(see section 4.4).</p><p>Based on the interaction study with grapefruit juice, it cannot be excluded that the concomitant<br />administration of sertraline&nbsp;and potent CYP3A4 inhibitors, e.g. protease inhibitors, ketoconazole,<br />itraconazole, posaconazole, voriconazole, clarithromycin, telithromycin and nefazodone, would result<br />in even larger increases in exposure of sertraline. This also concerns moderate CYP3A4 inhibitors, e.g.<br />aprepitant, erythromycin, fluconazole, verapamil and diltiazem. The intake of potent CYP3A4<br />inhibitors should be avoided during treatment with sertraline.</p><p>It cannot be excluded that CYP3A4 inducers, e.g. phenobarbital, carbamazepine,<br />St. John&acute;s Wort and rifampicin, may cause a reduction of sertraline plasma levels.</p><p>Sertraline&nbsp;plasma levels are enhanced by about 50% in poor metabolizers of CYP2C19 compared to<br />rapid metabolizers (see section 5.2). Interaction with strong inhibitors of CYP2C19, e.g. omeprazole,<br />lansoprazole, pantoprazole, rabeprazole, fluoxetine, fluvoxamine cannot be excluded.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u><br />There are no well controlled studies in pregnant women. However, a substantial amount of data did<br />not reveal evidence of induction of congenital malformations by sertraline. Animal studies showed<br />evidence for effects on reproduction probably due to maternal toxicity caused by the<br />pharmacodynamic action of the compound and/or direct pharmacodynamic action of the compound on<br />the foetus (see section 5.3).<br />Use of sertraline&nbsp;during pregnancy has been reported to cause symptoms, compatible with withdrawal<br />reactions, in some neonates, whose mothers had been on sertraline. This phenomenon has also been<br />observed with other SSRI antidepressants. Sertraline&nbsp;is not recommended in pregnancy, unless the<br />clinical condition of the woman is such that the benefit of the treatment is expected to outweigh the<br />potential risk.</p><p><u>Observational data identify an increased risk (less than two-fold) of postpartum haemorrhage following<br />exposure to SSRIs/SNRIs in the months preceding delivery&nbsp;(see sections 4.4 and 4.8).</u></p><p>Neonates should be observed if maternal use of sertraline&nbsp;continues into the later stages of pregnancy,<br />particularly the third trimester. The following symptoms may occur in the neonate after maternal<br />sertraline&nbsp;use in later stages of pregnancy: respiratory distress, cyanosis, apnoea, seizures, temperature<br />instability, feeding difficulty, vomiting, hypoglycaemia, hypertonia, hypotonia, hyperreflexia, tremor,<br />jitteriness, irritability, lethargy, constant crying, somnolence and difficulty in sleeping. These<br />symptoms could be due to either serotonergic effects or withdrawal symptoms. In a majority of<br />instances the complications begin immediately or soon (&lt;24 hours) after delivery.<br />Epidemiological data have suggested that the use of SSRIs in pregnancy, particular in late pregnancy,<br />may increase the risk of persistent pulmonary hypertension in the newborn (PPHN). The observed risk<br />was approximately 5 cases per 1000 pregnancies. In the general population 1 to 2 cases of PPHN per<br />1000 pregnancies occur.</p><p><u>Breast-feeding</u><br />Published data concerning sertraline&nbsp;levels in breast milk show that small quantities of sertraline&nbsp;and its<br />metabolite N-desmethylsertraline are excreted in milk. Generally negligible to undetectable levels<br />were found in infant serum, with one exception of an infant with serum levels about 50% of the<br />maternal level (but without a noticeable health effect in this infant).&nbsp;To date, no adverse effects on the health of infants nursed by mothers<br />using sertraline&nbsp;have been reported, but a risk cannot be excluded. Use in nursing mothers is not<br />recommended unless, in the judgment of the physician, the benefit outweighs the risk.</p><p><u>Fertility</u><br />Animal data did not show an effect of sertraline&nbsp;on fertility parameters (see section 5.3).</p><p>Human case reports with some SSRI&rsquo;s have shown that an effect on sperm quality is reversible.<br />Impact on human fertility has not been observed so far.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clinical pharmacology studies have shown that sertraline&nbsp;has no effect on psychomotor performance.<br />However, as psychotropic drugs may impair the mental or physical abilities required for the<br />performance of potentially hazardous tasks such as driving a car or operating machinery, the patient<br />should be cautioned accordingly.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Nausea is the most common undesirable effect. In the treatment of social anxiety disorder, sexual<br />dysfunction (ejaculation failure) in men occurred in 14% for sertraline&nbsp;vs 0% in placebo. These<br />undesirable effects are dose dependent and are often transient in nature with continued treatment.<br />The undesirable effects profile commonly observed in double-blind, placebo-controlled studies in<br />patients with OCD, panic disorder, PTSD and social anxiety disorder was similar to that observed in<br />clinical trials in patients with depression.<br />Table 1 displays adverse reactions observed from post-marketing experience (frequency not known)<br />and placebo-controlled clinical trials (comprising a total of 2542 patients on sertraline&nbsp;and 2145 on<br />placebo) in depression, OCD, panic disorder, PTSD and social anxiety disorder.<br />Some adverse drug reactions listed in Table 1 may decrease in intensity and frequency with continued<br />treatment and do not generally lead to cessation of therapy.</p><p><em>Table 1: Adverse Reactions</em></p><p>Frequency of adverse reactions observed from placebo-controlled clinical trials in depression, OCD, panic disorder, PTSD and social anxiety disorder. Pooled analysis and postmarketing experience (frequency not known).</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><u>Very</u> <u>Common</u> </strong><u>(&ge;1/10)</u></p></td><td style="vertical-align:top"><p><strong><u>Common</u></strong></p><p><u>(&ge;1/100 to</u></p><p><u>&lt;1/10)</u></p></td><td style="vertical-align:top"><p><strong><u>Uncommon</u></strong></p><p><u>(&ge;1/1000 to</u></p><p><u>&lt;1/100)</u></p></td><td style="vertical-align:top"><p><strong><u>Rare</u></strong></p><p><u>(&ge;1/10000 to</u></p><p><u>&lt;1/1000)</u></p></td><td style="vertical-align:top"><p><strong><u>Very rare</u></strong></p><p><u>(&lt;1/10000)</u></p></td><td style="vertical-align:top"><p><strong><u>Frequency not</u> <u>Known</u> <u>(cannot be</u> <u>estimated from</u> <u>the available</u> <u>data)</u></strong></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em><u>Infections and Infestations</u></em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Pharyngitis</u></p></td><td style="vertical-align:top"><p><u>Upper</u> <u>Respiratory</u> <u>Tract Infection,</u> <u>Rhinitis</u></p></td><td style="vertical-align:top"><p><u>Diverticulitis,</u> <u>Gastroenteritis, Otitis</u> <u>Media</u></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em><u>Neoplasms benign, malignant (including cysts and polyps)</u></em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Neoplasm&dagger;</u></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em><u>Blood and lymphatic system disorders</u></em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Lymphadenopathy</u></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Leukopenia,</u> <u>Thrombocytope</u> <u>nia</u></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em><u>Immune system disorders</u></em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Hypersensitivit</u> <u>y</u></p></td><td style="vertical-align:top"><p><u>Anaphylactoid</u> <u>Reaction</u></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Allergy</u></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em><u>Endocrine disorders</u></em></p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><u>Very</u> <u>Common</u> </strong><u>(&ge;1/10)</u></p></td><td style="vertical-align:top"><p><strong><u>Common</u></strong></p><p><u>(&ge;1/100 to</u></p><p><u>&lt;1/10)</u></p></td><td style="vertical-align:top"><p><strong><u>Uncommon</u></strong></p><p><u>(&ge;1/1000 to</u></p><p><u>&lt;1/100)</u></p></td><td style="vertical-align:top"><p><strong><u>Rare</u></strong></p><p><u>(&ge;1/10000 to</u></p><p><u>&lt;1/1000)</u></p></td><td style="vertical-align:top"><p><strong><u>Very rare</u></strong></p><p><u>(&lt;1/10000)</u></p></td><td style="vertical-align:top"><p><strong><u>Frequency not</u> <u>Known</u> <u>(cannot be</u> <u>estimated from</u> <u>the available</u> <u>data)</u></strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Hypothyroidis</u> <u>m</u></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:group
   id="Group_x0020_295" o:spid="_x0000_s1032" style='position:absolute;left:0;
   text-align:left;margin-left:3.45pt;margin-top:41.6pt;width:3.15pt;height:.6pt;
   z-index:-18977792;mso-wrap-distance-left:0;mso-wrap-distance-right:0;
   mso-position-horizontal-relative:text;mso-position-vertical-relative:text'
   coordsize="40005,7620" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Graphic_x0020_296" o:spid="_x0000_s1033" style='position:absolute;
    width:40005;height:7620;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="40005,7620" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m39624,l,,,7620r39624,l39624,xe" fillcolor="#5c2d91" stroked="f">
    <v:path arrowok="t"/>
   </v:shape></v:group><![endif]--><img width="5" height="1" src="file:///C:/Users/P20190~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><u>Hyperprolactina</u> <u>emia,</u> <u>iInappropriate</u> <s><u>a</u></s><u>Antidiuretic</u> <s><u>h</u></s><u>Hormone</u> <s><u>s</u></s><u>Secretion</u></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em><u>Metabolism and Nutrition Disorders</u></em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Decreased</u> <u>Appetite,</u> <u>Increased</u> <u>Appetite*</u></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Diabetes mellitus,</u> <u>Hypercholesterolaemi</u> <u>a, Hypoglycaemia</u></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:group id="Group_x0020_297" o:spid="_x0000_s1030"
   style='position:absolute;left:0;text-align:left;margin-left:3.45pt;
   margin-top:10.8pt;width:2.8pt;height:.6pt;z-index:-18977280;
   mso-wrap-distance-left:0;mso-wrap-distance-right:0;
   mso-position-horizontal-relative:text;mso-position-vertical-relative:text'
   coordsize="35560,7620" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Graphic_x0020_298" o:spid="_x0000_s1031" style='position:absolute;
    width:35560;height:7620;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="35560,7620" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m35051,l,,,7620r35051,l35051,xe" fillcolor="#5c2d91" stroked="f">
    <v:path arrowok="t"/>
   </v:shape></v:group><![endif]--><img width="4" height="1" src="file:///C:/Users/P20190~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /><u>&nbsp;Hyponatremia,</u> <s><u>h</u></s><u>Hyperglycaem</u> <u>ia</u></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em><u>Psychiatric Disorders</u></em></p></td></tr><tr><td style="vertical-align:top"><p><u>Insomnia</u> <u>(19%)</u></p></td><td style="vertical-align:top"><p><u>Depression*,</u> <u>Depersonalisation</u></p><p><u>, Nightmare,</u> <u>Anxiety*,</u> <u>Agitation*,</u> <u>Nervousness,</u> <u>Libido</u> <u>Decreased*,</u> <u>Bruxism</u></p></td><td style="vertical-align:top"><p><u>Hallucination*,</u> <u>Aggression*,</u> <u>Euphoric</u> <u>Mood*,</u> <u>Apathy,</u> <u>Thinking</u> <u>Abnormal</u></p></td><td style="vertical-align:top"><p><u>Conversion Disorder,</u> <u>Drug Dependence,</u> <u>Psychotic disorder*,</u> <u>Paranoia, Suicidal</u> <u>Ideation/behaviour**</u></p><p><u>*, Sleep Walking,</u> <u>Premature</u> <u>Ejaculation</u></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Paroniria</u></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em><u>Nervous System Disorders</u></em></p></td></tr><tr><td style="vertical-align:top"><p><u>Dizziness</u> <u>(11%),</u></p><p><u>Somnolenc</u> <u>e (13%),</u></p><p><u>Headache</u> <u>(21%)*</u></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:group
   id="Group_x0020_299" o:spid="_x0000_s1028" style='position:absolute;left:0;
   text-align:left;margin-left:45.05pt;margin-top:74.85pt;width:2.8pt;height:.6pt;
   z-index:-18976768;mso-wrap-distance-left:0;mso-wrap-distance-right:0;
   mso-position-horizontal-relative:text;mso-position-vertical-relative:text'
   coordsize="35560,7620" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Graphic_x0020_300" o:spid="_x0000_s1029" style='position:absolute;
    width:35560;height:7620;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="35560,7620" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m35051,l,,,7620r35051,l35051,xe" fillcolor="#5c2d91" stroked="f">
    <v:path arrowok="t"/>
   </v:shape></v:group><![endif]--><img width="3" height="1" src="file:///C:/Users/P20190~1/AppData/Local/Temp/msohtmlclip1/01/clip_image003.gif" /><u>Paraesthesia*,</u> <u>Tremor,</u> <u>Hypertonia,</u> <u>Dysgeusia,</u> <u>Disturbance in</u> <u>Attention</u><u>,</u></p></td><td style="vertical-align:top"><p><u>Convulsion*,</u> <u>Muscle</u> <u>Contractions</u> <u>Involuntary*,</u> <u>Coordination</u> <u>Abnormal,</u> <u>Hyperkinesia,</u> <u>Amnesia,</u> <u>Hypoaesthesia*</u></p><p><u>, Speech</u> <u>Disorder,</u> <u>Dizziness</u> <u>Postural,</u> <u>Syncope,</u> <u>Migraine*</u></p></td><td style="vertical-align:top"><p><u>Coma*,</u> <u>Choreoathetosis,</u> <u>Dyskinesia,</u> <u>Hyperaesthesia,</u> <u>Sensory Disturbance</u></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Movement</u> <u>Disorders</u> <u>(including</u> <u>extrapyramidal</u> <u>symptoms such</u> <u>as</u> <s><u>h</u></s><u>Hyperkinesia,</u> <s><u>h</u></s><u>Hypertonia,</u> <s><u>d</u></s><u>Dystonia,</u> <u>tTeeth</u> <s><u>g</u></s><u>Grinding or</u> <s><u>g</u></s><u>Gait</u> <s><u>a</u></s><u>Abnormalities)</u></p><p><!--[if gte vml 1]><v:group
   id="Group_x0020_301" o:spid="_x0000_s1026" style='position:absolute;left:0;
   text-align:left;margin-left:3.45pt;margin-top:-44.7pt;width:3.15pt;height:.6pt;
   z-index:-18976256;mso-wrap-distance-left:0;mso-wrap-distance-right:0'
   coordsize="40005,7620" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Graphic_x0020_302" o:spid="_x0000_s1027" style='position:absolute;
    width:40005;height:7620;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="40005,7620" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m39624,l,,,7619r39624,l39624,xe" fillcolor="#5c2d91" stroked="f">
    <v:path arrowok="t"/>
   </v:shape></v:group><![endif]--><img width="5" height="1" src="file:///C:/Users/P20190~1/AppData/Local/Temp/msohtmlclip1/01/clip_image004.gif" /><u>. Also reported</u> <u>were signs and</u> <u>symptoms</u> <u>associated with</u> <u>Serotonin</u> <u>Syndrome or</u></p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><u>Very</u> <u>Common</u> </strong><u>(&ge;1/10)</u></p></td><td style="vertical-align:top"><p><strong><u>Common</u></strong></p><p><u>(&ge;1/100 to</u></p><p><u>&lt;1/10)</u></p></td><td style="vertical-align:top"><p><strong><u>Uncommon</u></strong></p><p><u>(&ge;1/1000 to</u></p><p><u>&lt;1/100)</u></p></td><td style="vertical-align:top"><p><strong><u>Rare</u></strong></p><p><u>(&ge;1/10000 to</u></p><p><u>&lt;1/1000)</u></p></td><td style="vertical-align:top"><p><strong><u>Very rare</u></strong></p><p><u>(&lt;1/10000)</u></p></td><td style="vertical-align:top"><p><strong><u>Frequency not</u> <u>Known</u> <u>(cannot be</u> <u>estimated from</u> <u>the available</u> <u>data)</u></strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Neuroleptic</u> <u>Malignant</u> <u>Syndrome: In</u> <u>some cases</u> <u>associated with</u> <u>concomitant use</u> <u>of serotonergic</u> <u>drugs that</u> <u>included</u> <s><u>a</u></s><u>Agitation,</u> <s><u>c</u></s><u>Confusion,</u> <s><u>d</u></s><u>Diaphoresis,</u> <s><u>d</u></s><u>Diarrhoea,</u> <u>fFever,</u> <s><u>h</u></s><u>Hypertension,</u> <u>rRigidity, and</u> <u>tTachycardia.</u></p><p><!--[if gte vml 1]><v:group
   id="Group_x0020_304" o:spid="_x0000_s1036" style='position:absolute;left:0;
   text-align:left;margin-left:3.25pt;margin-top:-45pt;width:3.75pt;height:.6pt;
   z-index:-18975232;mso-wrap-distance-left:0;mso-wrap-distance-right:0'
   coordsize="47625,7620" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Graphic_x0020_305" o:spid="_x0000_s1037" style='position:absolute;
    width:47625;height:7620;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="47625,7620" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m47244,l,,,7620r47244,l47244,xe" fillcolor="#5c2d91" stroked="f">
    <v:path arrowok="t"/>
   </v:shape></v:group><![endif]--><img width="5" height="1" src="file:///C:/Users/P20190~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><!--[if gte vml 1]><v:group
   id="Group_x0020_306" o:spid="_x0000_s1034" style='position:absolute;left:0;
   text-align:left;margin-left:3.25pt;margin-top:-19.1pt;width:3.75pt;height:.6pt;
   z-index:-18974720;mso-wrap-distance-left:0;mso-wrap-distance-right:0'
   coordsize="47625,7620" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Graphic_x0020_307" o:spid="_x0000_s1035" style='position:absolute;
    width:47625;height:7620;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="47625,7620" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQAkmjgqxQAAANwAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9BawIx
FITvBf9DeIK3mqjQ6moULS3UQg+ugtfn5rm7uHlZklS3/fWmUOhxmJlvmMWqs424kg+1Yw2joQJB
XDhTc6nhsH97nIIIEdlg45g0fFOA1bL3sMDMuBvv6JrHUiQIhww1VDG2mZShqMhiGLqWOHln5y3G
JH0pjcdbgttGjpV6khZrTgsVtvRSUXHJv6wGf/zJZ6/Tjfo84X5bf+S787HcaD3od+s5iEhd/A//
td+Nhol6ht8z6QjI5R0AAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAAAAAA
AAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUBAAAL
AAAAAAAAAAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQAkmjgqxQAAANwAAAAP
AAAAAAAAAAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA+QIAAAAA
" path="m47244,l,,,7619r47244,l47244,xe" fillcolor="#5c2d91" stroked="f">
    <v:path arrowok="t"/>
   </v:shape></v:group><![endif]--><img width="5" height="1" src="file:///C:/Users/P20190~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /><!--[if gte vml 1]><v:group
   id="Group_x0020_308" o:spid="_x0000_s1032" style='position:absolute;left:0;
   text-align:left;margin-left:3.25pt;margin-top:-6pt;width:3.15pt;height:.6pt;
   z-index:-18974208;mso-wrap-distance-left:0;mso-wrap-distance-right:0'
   coordsize="40005,7620" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Graphic_x0020_309" o:spid="_x0000_s1033" style='position:absolute;
    width:40005;height:7620;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="40005,7620" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m39624,l,,,7620r39624,l39624,xe" fillcolor="#5c2d91" stroked="f">
    <v:path arrowok="t"/>
   </v:shape></v:group><![endif]--><img width="4" height="1" src="file:///C:/Users/P20190~1/AppData/Local/Temp/msohtmlclip1/01/clip_image003.gif" /><u>Akathisia and</u> <s><u>p</u></s><u>Pyschomotor</u> <u>rRestlessness</u> <u>(see section</u> <u>4.4),</u></p><p><!--[if gte vml 1]><v:group
   id="Group_x0020_310" o:spid="_x0000_s1030" style='position:absolute;left:0;
   text-align:left;margin-left:3.25pt;margin-top:-31.6pt;width:3.75pt;height:.6pt;
   z-index:-18973696;mso-wrap-distance-left:0;mso-wrap-distance-right:0'
   coordsize="47625,7620" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Graphic_x0020_311" o:spid="_x0000_s1031" style='position:absolute;
    width:47625;height:7620;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="47625,7620" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQBB5pMYxQAAANwAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Ba8JA
FITvgv9heYI33aRCsdFVVFqwBQ9Gwesz+0yC2bdhd6uxv75bEHocZuYbZr7sTCNu5HxtWUE6TkAQ
F1bXXCo4Hj5GUxA+IGtsLJOCB3lYLvq9OWba3nlPtzyUIkLYZ6igCqHNpPRFRQb92LbE0btYZzBE
6UqpHd4j3DTyJUlepcGa40KFLW0qKq75t1HgTj/52/t0nezOePisv/L95VSulRoOutUMRKAu/Ief
7a1WMElT+DsTj4Bc/AIAAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAAAAAA
AAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUBAAAL
AAAAAAAAAAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQBB5pMYxQAAANwAAAAP
AAAAAAAAAAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA+QIAAAAA
" path="m47244,l,,,7620r47244,l47244,xe" fillcolor="#5c2d91" stroked="f">
    <v:path arrowok="t"/>
   </v:shape></v:group><![endif]--><img width="5" height="1" src="file:///C:/Users/P20190~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><!--[if gte vml 1]><v:group
   id="Group_x0020_312" o:spid="_x0000_s1028" style='position:absolute;left:0;
   text-align:left;margin-left:3.25pt;margin-top:46.4pt;width:3.75pt;height:.6pt;
   z-index:-18973184;mso-wrap-distance-left:0;mso-wrap-distance-right:0'
   coordsize="47625,7620" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEAvJk5hKACAADXBgAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWy8VVFP2zAQfp+0/2D5HdKUFlhFQFsZ
1aQJEAXt+eq4TTTH9mw3pPv1Oztxk3ViE5u0l+Ts++58990X5+KqqQSpubGlkhlNj0eUcMlUXspN
Rp8eb47OKbEOZA5CSZ7RHbf06vLtmwuYbQzoomQEM0g7g4wWzulZklhW8ArssdJcom+tTAUOl2aT
5AaeMXMlkvFodJpUUEp62ae6Bgdka8q/SCUU+8rzOcgaLKYUbDbc6WoU7N8zw0zWC6OX+t74ytlt
fW9ImWcUmZNQIUU06RwdDJfJQdSmT9CsTeXxar0mTUanZ+en6Rhz7TJ6Op5O0nTa5uONIwwBkzPc
poShH61Rd1hx94dwVnx8OQGW15aBxqC0YPraXuj4JB3HnhdGbTXxGwfN+/CQ5zMOyLZUIGeLSMB/
Y6aldM/X69mwuqXi18mfpCc9D+034bciEz4gaiAG204+B9P/qcjfTHw/MBTg1roFV0FDUH+2Lhy7
yaMFRbRYI6NpOHNEZFRQ4jLqKDEZNZSsMrpqy9bgfJzv2JvkeS+8otOdd1Wq5o8qgJwX7+RsPJkE
6QaescoeIeQQOWgUUdEX3zpkazFR5C/C+kNfAY31xROZUJa3Q/L9hi92zwEePWTZKlHmN6UQvnFr
Nqu5MKQGpHM6H1+/Sz2DGDKA+VU3cNcsg45c80HlO59hhW+8QvAOdnf4WAuFZDNRakoKZb4f7j3j
rZtR+20LhlMiPkkbrh4XDRONVTSME3OF1Y3CVauNdY/NFzCaeBOnjzq7VcsCNA+AKCIsusf6QqV6
v3VqXXqFobOt2zuEdUu3E54/jPEPLvN7MPCAfQnwfxIuj56WHTGIwPCegK3lS/2AimzztgwFygKw
u4WSgyu984XPzf83huvLHwAAAP//AwBQSwMEFAAGAAgAAAAhAOFRNx/PBgAA5hsAABoAAABjbGlw
Ym9hcmQvdGhlbWUvdGhlbWUxLnhtbOxZzW/cRBS/I/E/jHxvs9/NRt1U2c1uA23aKNkW9Thrz9rT
jD3WzGzSvaH2iISEKIgDlbhxQEClVuJS/ppAERSp/wJvZmyvJ+uQtI2gguaQtZ9/877fm6/LV+7F
DB0QISlPel79Ys1DJPF5QJOw590ajy6sekgqnASY8YT0vDmR3pX199+7jNd8RtMJxyIYRyQmCBgl
cg33vEipdG1lRfpAxvIiT0kC36ZcxFjBqwhXAoEPQUDMVhq1WmclxjTx1oGj0oyGDP4lSmqCz8Se
ZkNQgmOQfnM6pT4x2GC/rhFyLgdMoAPMeh7wDPjhmNxTHmJYKvjQ82rmz1tZv7yC17JBTJ0wtjRu
ZP6ycdmAYL9hZIpwUgitj1rdS5sFfwNgahk3HA4Hw3rBzwCw74OlVpcyz9Zotd7PeZZA9nGZ96DW
rrVcfIl/c0nnbr/fb3czXSxTA7KPrSX8aq3T2mg4eAOy+PYSvtXfGAw6Dt6ALL6zhB9d6nZaLt6A
IkaT/SW0DuholHEvIFPOtirhqwBfrWXwBQqyocguLWLKE3VSrsX4LhcjAGggw4omSM1TMsU+5OQA
xxNBsRaA1wgufbEkXy6RtCwkfUFT1fM+THHilSAvn33/8tkTdHT/6dH9n44ePDi6/6Nl5IzawklY
HvXi28/+fPQx+uPJNy8eflGNl2X8rz988svPn1cDoXwW5j3/8vFvTx8//+rT3797WAHfEHhSho9p
TCS6QQ7RLo/BMOMVV3MyEa82YhxhWh6xkYQSJ1hLqeA/VJGDvjHHLIuOo0efuB68LaB9VAGvzu46
Cu9FYqZoheRrUewAtzlnfS4qvXBNyyq5eTxLwmrhYlbG7WJ8UCV7gBMnvsNZCn0zT0vH8EFEHDV3
GE4UDklCFNLf+D4hFdbdodTx6zb1BZd8qtAdivqYVrpkTCdONi0GbdEY4jKvshni7fhm+zbqc1Zl
9SY5cJFQFZhVKD8mzHHjVTxTOK5iOcYxKzv8OlZRlZJ7c+GXcUOpINIhYRwNAyJl1ZibAuwtBf0a
ho5VGfZtNo9dpFB0v4rndcx5GbnJ9wcRjtMq7B5NojL2A7kPKYrRDldV8G3uVoh+hzjg5MRw36bE
Cffp3eAWDR2VFgmiv8yEjiW0aqcDxzT5u3bMKPRjmwPn146hAT7/+lFFZr2tjXgD5qSqStg61n5P
wh1vugMuAvr299xNPEt2CKT58sTzruW+a7nef77lnlTPZ220i94KbVevG+yi2CyR4xNXyFPK2J6a
M3JdmkWyhHkiGAFRjzM7QVLsmNIIHrO+7uBCgc0YJLj6iKpoL8IpLLDrnmYSyox1KFHKJWzsDLmS
t8bDIl3ZbWFbbxhsP5BYbfPAkpuanO8LCjZmtgnN5jMX1NQMziqseSljCma/jrC6VurM0upGNdPq
HGmFyRDDZdOAWHgTFiAIli3g5Q7sxbVo2JhgRgLtdzv35mExUTjPEMkIBySLkbZ7OUZ1E6Q8V8xJ
AORORYz0Ju8Ur5WkdTXbN5B2liCVxbVOEJdH702ilGfwIkq6bo+VI0vKxckSdNjzuu1G20M+Tnve
FPa08BinEHWp13yYhXAa5Cth0/7UYjZVvohmNzfMLYI6HFNYvy8Z7PSBVEi1iWVkU8N8ylKAJVqS
1b/RBreelwE2019Di+YqJMO/pgX40Q0tmU6Jr8rBLlG07+xr1kr5TBGxFwWHaMJmYhdD+HWqgj0B
lXA0YTqCfoFzNO1t88ltzlnRlU+vDM7SMUsjnLVbXaJ5JVu4qeNCB/NWUg9sq9TdGPfqppiSPydT
ymn8PzNFzydwUtAMdAR8OJQVGOl67XlcqIhDF0oj6o8ELBxM74BsgbNY+AxJBSfI5leQA/1ra87y
MGUNGz61S0MkKMxHKhKE7EBbMtl3CrN6NndZlixjZDKqpK5MrdoTckDYWPfAjp7bPRRBqptukrUB
gzuef+57VkGTUC9yyvXm9JBi7rU18E+vfGwxg1FuHzYLmtz/hYoVs6odb4bnc2/ZEP1hscxq5VUB
wkpTQTcr+9dU4RWnWtuxlixutHPlIIrLFgOxWBClcN6D9D+Y/6jwmb1t0BPqmO9Cb0Vw0aCZQdpA
Vl+wCw+kG6QlTmDhZIk2mTQr69ps6aS9lk/W57zSLeQec7bW7CzxfkVnF4szV5xTi+fp7MzDjq8t
7URXQ2SPlyiQpvlGxgSm6tZpG6doEtZ7Htz8QKDvwRPcHXlAa2haQ9PgCS6EYLFkb3F6XvaQU+C7
pRSYZk5p5phWTmnllHZOgcVZdl+SUzrQqfQVB1yx6R8P5bcZsILLbj/ypupcza3/BQAA//8DAFBL
AwQUAAYACAAAACEAnGZGQbsAAAAkAQAAKgAAAGNsaXBib2FyZC9kcmF3aW5ncy9fcmVscy9kcmF3
aW5nMS54bWwucmVsc4SPzQrCMBCE74LvEPZu0noQkSa9iNCr1AcIyTYtNj8kUezbG+hFQfCyMLPs
N7NN+7IzeWJMk3ccaloBQae8npzhcOsvuyOQlKXTcvYOOSyYoBXbTXPFWeZylMYpJFIoLnEYcw4n
xpIa0cpEfUBXNoOPVuYio2FBqrs0yPZVdWDxkwHii0k6zSF2ugbSL6Ek/2f7YZgUnr16WHT5RwTL
pRcWoIwGMwdKV2edNS1dgYmGff0m3gAAAP//AwBQSwECLQAUAAYACAAAACEAu+VIlAUBAAAeAgAA
EwAAAAAAAAAAAAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQCtMD/x
wQAAADIBAAALAAAAAAAAAAAAAAAAADYBAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQC8mTmE
oAIAANcGAAAfAAAAAAAAAAAAAAAAACACAABjbGlwYm9hcmQvZHJhd2luZ3MvZHJhd2luZzEueG1s
UEsBAi0AFAAGAAgAAAAhAOFRNx/PBgAA5hsAABoAAAAAAAAAAAAAAAAA/QQAAGNsaXBib2FyZC90
aGVtZS90aGVtZTEueG1sUEsBAi0AFAAGAAgAAAAhAJxmRkG7AAAAJAEAACoAAAAAAAAAAAAAAAAA
BAwAAGNsaXBib2FyZC9kcmF3aW5ncy9fcmVscy9kcmF3aW5nMS54bWwucmVsc1BLBQYAAAAABQAF
AGcBAAAHDQAAAAA=
">
   <v:shape id="Graphic_x0020_313" o:spid="_x0000_s1029" style='position:absolute;
    width:47625;height:7620;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="47625,7620" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m47244,l,,,7620r47244,l47244,xe" fillcolor="#5c2d91" stroked="f">
    <v:path arrowok="t"/>
   </v:shape></v:group><![endif]--><img width="5" height="1" src="file:///C:/Users/P20190~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><u>Cerebrovascula</u> <u>r Spasm</u> <u>(including</u> <u>rReversible</u> <s><u>c</u></s><u>Cerebral</u> <s><u>v</u></s><u>Vasconstrictio</u> <u>n <s>s</s>Syndrome</u> <u>and Call-</u> <u>Fleming</u> <s><u>s</u></s><u>Syndrome).</u></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em><u>Eye Disorders</u></em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Visual</u> <u>Disturbance</u></p></td><td style="vertical-align:top"><p><u>Mydriasis*</u></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:group
   id="Group_x0020_314" o:spid="_x0000_s1026" style='position:absolute;left:0;
   text-align:left;margin-left:51pt;margin-top:62.75pt;width:2.8pt;height:.6pt;
   z-index:-18972672;mso-wrap-distance-left:0;mso-wrap-distance-right:0;
   mso-position-horizontal-relative:text;mso-position-vertical-relative:text'
   coordsize="35560,7620" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Graphic_x0020_315" o:spid="_x0000_s1027" style='position:absolute;
    width:35560;height:7620;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="35560,7620" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQCnB8QMxgAAANwAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI/RasJA
FETfhf7DcoW+6SZqpY2uooVCsYpW+wHX7DWJzd4N2W2Mf98VBB+HmTnDTOetKUVDtSssK4j7EQji
1OqCMwU/h4/eKwjnkTWWlknBlRzMZ0+dKSbaXvibmr3PRICwS1BB7n2VSOnSnAy6vq2Ig3eytUEf
ZJ1JXeMlwE0pB1E0lgYLDgs5VvSeU/q7/zMKztuvcjmKD9l6NdxUm+O5Wezetko9d9vFBISn1j/C
9/anVjCMX+B2JhwBOfsHAAD//wMAUEsBAi0AFAAGAAgAAAAhANvh9svuAAAAhQEAABMAAAAAAAAA
AAAAAAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAWvQsW78AAAAVAQAA
CwAAAAAAAAAAAAAAAAAfAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEApwfEDMYAAADcAAAA
DwAAAAAAAAAAAAAAAAAHAgAAZHJzL2Rvd25yZXYueG1sUEsFBgAAAAADAAMAtwAAAPoCAAAAAA==
" path="m35051,l,,,7620r35051,l35051,xe" fillcolor="#5c2d91" stroked="f">
    <v:path arrowok="t"/>
   </v:shape></v:group><![endif]--><img width="4" height="1" src="file:///C:/Users/P20190~1/AppData/Local/Temp/msohtmlclip1/01/clip_image004.gif" /><u>Glaucoma, Lacrimal</u> <u>Disorder, Scotoma,</u> <u>Diplopia,</u> <u>Photophobia,</u> <u>Hyphaema</u><u>,</u></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Vision</u> <u>Abnormal,</u> <u>Pupils Unequal</u></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em><u>Ear and Labyrinth Disorders</u></em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Tinnitus*</u></p></td><td style="vertical-align:top"><p><u>Ear Pain</u></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em><u>Cardiac Disorders</u></em></p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><u>Very</u> <u>Common</u> </strong><u>(&ge;1/10)</u></p></td><td style="vertical-align:top"><p><strong><u>Common</u></strong></p><p><u>(&ge;1/100 to</u></p><p><u>&lt;1/10)</u></p></td><td style="vertical-align:top"><p><strong><u>Uncommon</u></strong></p><p><u>(&ge;1/1000 to</u></p><p><u>&lt;1/100)</u></p></td><td style="vertical-align:top"><p><strong><u>Rare</u></strong></p><p><u>(&ge;1/10000 to</u></p><p><u>&lt;1/1000)</u></p></td><td style="vertical-align:top"><p><strong><u>Very rare</u></strong></p><p><u>(&lt;1/10000)</u></p></td><td style="vertical-align:top"><p><strong><u>Frequency not</u> <u>Known</u> <u>(cannot be</u> <u>estimated from</u> <u>the available</u> <u>data)</u></strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Palpitations*</u></p></td><td style="vertical-align:top"><p><u>Tachycardia</u></p></td><td style="vertical-align:top"><p><u>Myocardial</u> <u>Infarction,</u> <u>Bradycardia, Cardiac</u> <u>Disorder</u></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>QTc</u> <s><u>p</u></s><u>Prolongation</u> <u>(see sections</u> <u>4.4, 4.5 and</u></p><p><u>5.1), Torsade de</u> <u>Pointes (see</u> <u>sections 4.4, 4.5</u> <u>and 5.1)</u></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em><u>Vascular Disorders</u></em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Hot flush*</u></p></td><td style="vertical-align:top"><p><u>Hypertension*,</u> <u>Flushing</u></p></td><td style="vertical-align:top"><p><u>Peripheral Ischaemia,</u> <u>Haematuria</u></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:group
   id="Group_x0020_317" o:spid="_x0000_s1030" style='position:absolute;left:0;
   text-align:left;margin-left:12.65pt;margin-top:36.85pt;width:2.8pt;height:.6pt;
   z-index:-18971648;mso-wrap-distance-left:0;mso-wrap-distance-right:0;
   mso-position-horizontal-relative:text;mso-position-vertical-relative:text'
   coordsize="35560,7620" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEAmGM2+6MCAADXBgAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWy8VVFP2zAQfp+0/2D5HZJSUmhFQFsZ
1SQEFS3as+s4TTTH9mw3pPv1Oztxk3ViE5u0l+Ts++58990X5+qmqTiqmTalFCkencYYMUFlVopt
ip/XdyeXGBlLREa4FCzFe2bwzfX7d1dkttVEFSVFkEGYGUlxYa2aRZGhBauIOZWKCfDlUlfEwlJv
o0yTF8hc8egsjidRRUqBr/tUt8QStNPlX6Tikn5l2ZyImhhIyelsuNPVyOm/ZyYzUS+0WqmldpXT
h3qpUZmlGJgTpAKKcNQ5Ohgso6OobZ+gyXXl8DLPUZPiZBqfX04SjPYpPo+TaZIkbT7WWEQBME6S
CRxFwX8xOYu7w4rHP4TT4tPrCaC8tgwwBqV509X2Ssfj0UXoeaHlTiG3cdS8C/d57mFApqUCOFsE
Av4bM8AZUHbg6+1sGNVS8evkxyP4SNrZL7pvwm0FJlxA0EAINp18jqb/U5G/mfhhYCDAnbELJr2G
SH1vrD92mwWLFMGijQimZtQinmKOkU2xxUinWGO0SfGmLVsR6+Jcx85ELwfhFZ3unKuSNVtLD7JO
vOMkTkY9z1Blj+BiiBw0CqjgC2/ls7WYIPJXYf2hb4B6HQxSUi4Na4fk+vVf7IEDwA1ZNpKX2V3J
uWvc6O1mzjWqCdCZzM9upyPHIIQMYG7VDdw2K68j23yU2d5l2MAbrhC4g+0jPHIugWzKS4VRIfX3
470XUFiKzbcd0Qwj/lkYf/XYYOhgbIKhLZ9LqC72V63Sxq6bL0Qr5EyYPujsQa4KopgHBBFB0T3W
FSrkh52VeekUBs62bufgxq7snjv+IMY9mMiWRJMn6IsT9ydh4uR51REDCAjvCdgZtlJPoMg2b8uQ
p8wDu1soOrrSO5//Bbn/xnB9/QMAAP//AwBQSwMEFAAGAAgAAAAhAOFRNx/PBgAA5hsAABoAAABj
bGlwYm9hcmQvdGhlbWUvdGhlbWUxLnhtbOxZzW/cRBS/I/E/jHxvs9/NRt1U2c1uA23aKNkW9Thr
z9rTjD3WzGzSvaH2iISEKIgDlbhxQEClVuJS/ppAERSp/wJvZmyvJ+uQtI2gguaQtZ9/877fm6/L
V+7FDB0QISlPel79Ys1DJPF5QJOw590ajy6sekgqnASY8YT0vDmR3pX199+7jNd8RtMJxyIYRyQm
CBglcg33vEipdG1lRfpAxvIiT0kC36ZcxFjBqwhXAoEPQUDMVhq1WmclxjTx1oGj0oyGDP4lSmqC
z8SeZkNQgmOQfnM6pT4x2GC/rhFyLgdMoAPMeh7wDPjhmNxTHmJYKvjQ82rmz1tZv7yC17JBTJ0w
tjRuZP6ycdmAYL9hZIpwUgitj1rdS5sFfwNgahk3HA4Hw3rBzwCw74OlVpcyz9Zotd7PeZZA9nGZ
96DWrrVcfIl/c0nnbr/fb3czXSxTA7KPrSX8aq3T2mg4eAOy+PYSvtXfGAw6Dt6ALL6zhB9d6nZa
Lt6AIkaT/SW0DuholHEvIFPOtirhqwBfrWXwBQqyocguLWLKE3VSrsX4LhcjAGggw4omSM1TMsU+
5OQAxxNBsRaA1wgufbEkXy6RtCwkfUFT1fM+THHilSAvn33/8tkTdHT/6dH9n44ePDi6/6Nl5Iza
wklYHvXi28/+fPQx+uPJNy8eflGNl2X8rz988svPn1cDoXwW5j3/8vFvTx8//+rT3797WAHfEHhS
ho9pTCS6QQ7RLo/BMOMVV3MyEa82YhxhWh6xkYQSJ1hLqeA/VJGDvjHHLIuOo0efuB68LaB9VAGv
zu46Cu9FYqZoheRrUewAtzlnfS4qvXBNyyq5eTxLwmrhYlbG7WJ8UCV7gBMnvsNZCn0zT0vH8EFE
HDV3GE4UDklCFNLf+D4hFdbdodTx6zb1BZd8qtAdivqYVrpkTCdONi0GbdEY4jKvshni7fhm+zbq
c1Zl9SY5cJFQFZhVKD8mzHHjVTxTOK5iOcYxKzv8OlZRlZJ7c+GXcUOpINIhYRwNAyJl1ZibAuwt
Bf0aho5VGfZtNo9dpFB0v4rndcx5GbnJ9wcRjtMq7B5NojL2A7kPKYrRDldV8G3uVoh+hzjg5MRw
36bECffp3eAWDR2VFgmiv8yEjiW0aqcDxzT5u3bMKPRjmwPn146hAT7/+lFFZr2tjXgD5qSqStg6
1n5Pwh1vugMuAvr299xNPEt2CKT58sTzruW+a7nef77lnlTPZ220i94KbVevG+yi2CyR4xNXyFPK
2J6aM3JdmkWyhHkiGAFRjzM7QVLsmNIIHrO+7uBCgc0YJLj6iKpoL8IpLLDrnmYSyox1KFHKJWzs
DLmSt8bDIl3ZbWFbbxhsP5BYbfPAkpuanO8LCjZmtgnN5jMX1NQMziqseSljCma/jrC6VurM0upG
NdPqHGmFyRDDZdOAWHgTFiAIli3g5Q7sxbVo2JhgRgLtdzv35mExUTjPEMkIBySLkbZ7OUZ1E6Q8
V8xJAORORYz0Ju8Ur5WkdTXbN5B2liCVxbVOEJdH702ilGfwIkq6bo+VI0vKxckSdNjzuu1G20M+
TnveFPa08BinEHWp13yYhXAa5Cth0/7UYjZVvohmNzfMLYI6HFNYvy8Z7PSBVEi1iWVkU8N8ylKA
JVqS1b/RBreelwE2019Di+YqJMO/pgX40Q0tmU6Jr8rBLlG07+xr1kr5TBGxFwWHaMJmYhdD+HWq
gj0BlXA0YTqCfoFzNO1t88ltzlnRlU+vDM7SMUsjnLVbXaJ5JVu4qeNCB/NWUg9sq9TdGPfqppiS
PydTymn8PzNFzydwUtAMdAR8OJQVGOl67XlcqIhDF0oj6o8ELBxM74BsgbNY+AxJBSfI5leQA/1r
a87yMGUNGz61S0MkKMxHKhKE7EBbMtl3CrN6NndZlixjZDKqpK5MrdoTckDYWPfAjp7bPRRBqptu
krUBgzuef+57VkGTUC9yyvXm9JBi7rU18E+vfGwxg1FuHzYLmtz/hYoVs6odb4bnc2/ZEP1hscxq
5VUBwkpTQTcr+9dU4RWnWtuxlixutHPlIIrLFgOxWBClcN6D9D+Y/6jwmb1t0BPqmO9Cb0Vw0aCZ
QdpAVl+wCw+kG6QlTmDhZIk2mTQr69ps6aS9lk/W57zSLeQec7bW7CzxfkVnF4szV5xTi+fp7MzD
jq8t7URXQ2SPlyiQpvlGxgSm6tZpG6doEtZ7Htz8QKDvwRPcHXlAa2haQ9PgCS6EYLFkb3F6XvaQ
U+C7pRSYZk5p5phWTmnllHZOgcVZdl+SUzrQqfQVB1yx6R8P5bcZsILLbj/ypupcza3/BQAA//8D
AFBLAwQUAAYACAAAACEAnGZGQbsAAAAkAQAAKgAAAGNsaXBib2FyZC9kcmF3aW5ncy9fcmVscy9k
cmF3aW5nMS54bWwucmVsc4SPzQrCMBCE74LvEPZu0noQkSa9iNCr1AcIyTYtNj8kUezbG+hFQfCy
MLPsN7NN+7IzeWJMk3ccaloBQae8npzhcOsvuyOQlKXTcvYOOSyYoBXbTXPFWeZylMYpJFIoLnEY
cw4nxpIa0cpEfUBXNoOPVuYio2FBqrs0yPZVdWDxkwHii0k6zSF2ugbSL6Ek/2f7YZgUnr16WHT5
RwTLpRcWoIwGMwdKV2edNS1dgYmGff0m3gAAAP//AwBQSwECLQAUAAYACAAAACEAu+VIlAUBAAAe
AgAAEwAAAAAAAAAAAAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQCt
MD/xwQAAADIBAAALAAAAAAAAAAAAAAAAADYBAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQCY
Yzb7owIAANcGAAAfAAAAAAAAAAAAAAAAACACAABjbGlwYm9hcmQvZHJhd2luZ3MvZHJhd2luZzEu
eG1sUEsBAi0AFAAGAAgAAAAhAOFRNx/PBgAA5hsAABoAAAAAAAAAAAAAAAAAAAUAAGNsaXBib2Fy
ZC90aGVtZS90aGVtZTEueG1sUEsBAi0AFAAGAAgAAAAhAJxmRkG7AAAAJAEAACoAAAAAAAAAAAAA
AAAABwwAAGNsaXBib2FyZC9kcmF3aW5ncy9fcmVscy9kcmF3aW5nMS54bWwucmVsc1BLBQYAAAAA
BQAFAGcBAAAKDQAAAAA=
">
   <v:shape id="Graphic_x0020_318" o:spid="_x0000_s1031" style='position:absolute;
    width:35560;height:7620;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="35560,7620" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m35051,l,,,7620r35051,l35051,xe" fillcolor="#5c2d91" stroked="f">
    <v:path arrowok="t"/>
   </v:shape></v:group><![endif]--><img width="4" height="1" src="file:///C:/Users/P20190~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><u>Abnormal</u> <u>Bleeding (such</u> <u>as</u><u>,</u> <s><u>g</u></s><u>Gastrointestin</u> <u>al <s>b</s>Bleeding )</u></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em><u>Respiratory, Thoracic, and Mediastinal Disorders</u></em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Yawning*</u></p></td><td style="vertical-align:top"><p><u>Bronchospasm*</u></p><p><u>, Dyspnoea,</u> <u>Epistaxis</u></p></td><td style="vertical-align:top"><p>Laryngospasm, Hyperventilation, , eosinophilic<br />pneumonia*&sect;,Hypoventilation, Stridor, Dysphonia, Hiccups</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Interstitial Lung</u> <u>Disease</u></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em><u>Gastrointestinal Disorders</u></em></p></td></tr><tr><td style="vertical-align:top"><p><u>Diarrhoea</u> <u>(18%),</u></p><p><u>Nausea</u> <u>(24%), Dry</u></p><p><u>Mouth</u> <u>(14%)</u></p></td><td style="vertical-align:top"><p><u>Abdominal</u> <u>Pain*,</u> <u>Vomiting*,</u> <u>Constipation*,</u> <u>Dyspepsia,</u> <u>Flatulence</u></p></td><td style="vertical-align:top"><p><u>Oesophagitis,</u> <u>Dysphagia,</u> <u>Haemorrhoids,</u> <u>Salivary</u> <u>Hypersecretion,</u> <u>Tongue</u> <u>Disorder,</u> <u>Eructation</u></p></td><td style="vertical-align:top"><p><u>Melaena,</u> <u>Haematochezia,</u> <u>Stomatitis, Tongue</u> <s><u>u</u></s><u>Ulceration, Tooth</u> <u>Disorder, Glossitis,</u> <u>Mouth Ulceration</u></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Pancreatitis</u></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em><u>Hepatobiliary Disorders</u></em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Hepatic Function</u> <u>Abnormal</u></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:group
   id="Group_x0020_319" o:spid="_x0000_s1028" style='position:absolute;left:0;
   text-align:left;margin-left:3.4pt;margin-top:62.75pt;width:3.15pt;height:.6pt;
   z-index:-18971136;mso-wrap-distance-left:0;mso-wrap-distance-right:0;
   mso-position-horizontal-relative:text;mso-position-vertical-relative:text'
   coordsize="40005,7620" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Graphic_x0020_320" o:spid="_x0000_s1029" style='position:absolute;
    width:40005;height:7620;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="40005,7620" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m39624,l,,,7619r39624,l39624,xe" fillcolor="#5c2d91" stroked="f">
    <v:path arrowok="t"/>
   </v:shape></v:group><![endif]--><img width="4" height="1" src="file:///C:/Users/P20190~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /><!--[if gte vml 1]><v:group
   id="Group_x0020_321" o:spid="_x0000_s1026" style='position:absolute;left:0;
   text-align:left;margin-left:3.4pt;margin-top:88.8pt;width:3.75pt;height:.6pt;
   z-index:-18970624;mso-wrap-distance-left:0;mso-wrap-distance-right:0;
   mso-position-horizontal-relative:text;mso-position-vertical-relative:text'
   coordsize="47625,7620" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Graphic_x0020_322" o:spid="_x0000_s1027" style='position:absolute;
    width:47625;height:7620;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="47625,7620" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m47244,l,,,7620r47244,l47244,xe" fillcolor="#5c2d91" stroked="f">
    <v:path arrowok="t"/>
   </v:shape></v:group><![endif]--><img width="5" height="1" src="file:///C:/Users/P20190~1/AppData/Local/Temp/msohtmlclip1/01/clip_image003.gif" /><u>Serious liver</u> <u>events</u> <u>(including</u> <s><u>h</u></s><u>Hepatitis,</u> <u>jJaundice, and</u> <u>Hepatic</u> <u>fFailure)</u></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em><u>Skin and Subcutaneous Tissue Disorders</u></em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Rash*,</u> <u>Hyperhidrosis</u></p></td><td style="vertical-align:top"><p><u>Periorbital</u> <u>Oedema*,</u> <u>Face Oedema,</u> <u>Purpura*,</u></p></td><td style="vertical-align:top"><p><u>Dermatitis,</u> <u>Dermatitis Bullous,</u> <u>Rash Follicular, Hair</u> <u>Texture Abnormal,</u></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Rare reports of</u> <u>severe</u> <u>cutaneous</u> <u>adverse</u></p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><u>Very</u> <u>Common</u> </strong><u>(&ge;1/10)</u></p></td><td style="vertical-align:top"><p><strong><u>Common</u></strong></p><p><u>(&ge;1/100 to</u></p><p><u>&lt;1/10)</u></p></td><td style="vertical-align:top"><p><strong><u>Uncommon</u></strong></p><p><u>(&ge;1/1000 to</u></p><p><u>&lt;1/100)</u></p></td><td style="vertical-align:top"><p><strong><u>Rare</u></strong></p><p><u>(&ge;1/10000 to</u></p><p><u>&lt;1/1000)</u></p></td><td style="vertical-align:top"><p><strong><u>Very rare</u></strong></p><p><u>(&lt;1/10000)</u></p></td><td style="vertical-align:top"><p><strong><u>Frequency not</u> <u>Known</u> <u>(cannot be</u> <u>estimated from</u> <u>the available</u> <u>data)</u></strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:group
   id="Group_x0020_324" o:spid="_x0000_s1035" style='position:absolute;left:0;
   text-align:left;margin-left:48pt;margin-top:49.55pt;width:2.8pt;height:.6pt;
   z-index:-18969600;mso-wrap-distance-left:0;mso-wrap-distance-right:0;
   mso-position-horizontal-relative:text;mso-position-vertical-relative:text'
   coordsize="35560,7620" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Graphic_x0020_325" o:spid="_x0000_s1036" style='position:absolute;
    width:35560;height:7620;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="35560,7620" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m35051,l,,,7620r35051,l35051,xe" fillcolor="#5c2d91" stroked="f">
    <v:path arrowok="t"/>
   </v:shape></v:group><![endif]--><img width="4" height="1" src="file:///C:/Users/P20190~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><u>Alopecia*,</u> <u>Cold Sweat,</u> <u>Dry </u><s><u>s</u></s><u>Skin,</u> <u>Urtica</u><s><u>u</u></s><u>ria,*,</u> <u>Pruritus</u></p></td><td style="vertical-align:top"><p><u>Skin Odour</u> <u>Abnormal</u></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>reactions</u> <u>(SCAR): e.g.</u></p><p><u>Stevens-</u> <u>Johnson</u> <s><u>s</u></s><u>Syndrome and</u> <s><u>e</u></s><u>Epidermal</u> <s><u>n</u></s><u>Necrolysis,</u> <u>Angioedema,</u> <u>Photosensitivity</u></p><p><!--[if gte vml 1]><v:group id="Group_x0020_326"
   o:spid="_x0000_s1033" style='position:absolute;left:0;text-align:left;
   margin-left:71.1pt;margin-top:7.2pt;width:2.8pt;height:.6pt;z-index:-18969088;
   mso-wrap-distance-left:0;mso-wrap-distance-right:0' coordsize="35560,7620"
   o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Graphic_x0020_327" o:spid="_x0000_s1034" style='position:absolute;
    width:35560;height:7620;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="35560,7620" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m35051,l,,,7619r35051,l35051,xe" fillcolor="#5c2d91" stroked="f">
    <v:path arrowok="t"/>
   </v:shape></v:group><![endif]--><img width="3" height="1" src="file:///C:/Users/P20190~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /><u>, Skin Reaction,</u></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em><u>Musculoskeletal and Connective Tissue Disorders</u></em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Arthralgia,</u> <u>Myalgia</u></p></td><td style="vertical-align:top"><p><u>Osteoarthritis,</u> <u>Muscular</u> <u>Weakness,</u> <u>Back Pain,</u> <u>Muscle</u> <u>Twitching</u></p></td><td style="vertical-align:top"><p><u>Bone Disorder</u></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Trismus*,</u> <u>Muscle Cramps</u></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em><u>Renal and Urinary Disorders</u></em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:group
   id="Group_x0020_328" o:spid="_x0000_s1031" style='position:absolute;left:0;
   text-align:left;margin-left:65.75pt;margin-top:114.7pt;width:2.65pt;
   height:.6pt;z-index:-18968576;mso-wrap-distance-left:0;
   mso-wrap-distance-right:0;mso-position-horizontal-relative:text;
   mso-position-vertical-relative:text' coordsize="33655,7620" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Graphic_x0020_329" o:spid="_x0000_s1032" style='position:absolute;
    width:33655;height:7620;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="33655,7620" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m33527,l,,,7619r33527,l33527,xe" fillcolor="#5c2d91" stroked="f">
    <v:path arrowok="t"/>
   </v:shape></v:group><![endif]--><img width="3" height="1" src="file:///C:/Users/P20190~1/AppData/Local/Temp/msohtmlclip1/01/clip_image003.gif" /><u>Nocturia,</u> <u>Urinary</u> <u>Retention*,</u> <u>Polyuria,</u> <u>Pollakiuria,</u> <u>Micturition</u> <s><u>d</u></s><u>Disorder,</u> <u>Urinary</u> <u>Incontinence*</u><u>,</u></p></td><td style="vertical-align:top"><p><u>Oliguria, Urinary</u> <u>Hesitation</u></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em><u>Reproductive System and Breast Disorders**</u></em></p></td></tr><tr><td style="vertical-align:top"><p><u>Ejaculation</u> <u>Failure</u> <u>(14%)</u></p></td><td style="vertical-align:top"><p><u>Erectile</u> <u>Dysfunction</u></p></td><td style="vertical-align:top"><p><u>Vaginal</u> <u>Haemorrhage,</u> <u>Sexual</u> <u>Dysfunction,</u> <u>Female Sexual</u> <u>Dysfunction,</u> <u>Menstruation</u> <u>Irregular</u></p></td><td style="vertical-align:top"><p><u>Menorrhagia,</u> <u>Atrophic</u> <u>Vulvuvaginitis,</u> <u>Balanoposthitis,</u> <u>Genital Discharge,</u> <u>Priapism*,</u> <u>Galactorrhoea*</u></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Gynaecomastia,</u></p><p>,</p><p><!--[if gte vml 1]><v:group
   id="Group_x0020_330" o:spid="_x0000_s1028" style='position:absolute;left:0;
   text-align:left;margin-left:3.4pt;margin-top:-5.25pt;width:2.8pt;height:4.6pt;
   z-index:-18968064;mso-wrap-distance-left:0;mso-wrap-distance-right:0'
   coordsize="35560,58419" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Graphic_x0020_331" o:spid="_x0000_s1029" style='position:absolute;
    top:51816;width:35560;height:6350;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="35560,6350" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m35051,l,,,6095r35051,l35051,xe" fillcolor="#d13438" stroked="f">
    <v:path arrowok="t"/>
   </v:shape><v:shape id="Graphic_x0020_332" o:spid="_x0000_s1030" style='position:absolute;
    width:35560;height:7620;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="35560,7620" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m35051,l,,,7620r35051,l35051,xe" fillcolor="#5c2d91" stroked="f">
    <v:path arrowok="t"/>
   </v:shape></v:group><![endif]--><img width="3" height="6" src="file:///C:/Users/P20190~1/AppData/Local/Temp/msohtmlclip1/01/clip_image004.gif" /><u>postpartum</u> <u>haemorrhage*&dagger;</u></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em><u>General Disorders and Administration Site Conditions</u></em></p></td></tr><tr><td style="vertical-align:top"><p><u>Fatigue</u> <u>(10%)*</u></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:group
   id="Group_x0020_333" o:spid="_x0000_s1026" style='position:absolute;left:0;
   text-align:left;margin-left:43.8pt;margin-top:23.85pt;width:2.65pt;height:.6pt;
   z-index:-18967552;mso-wrap-distance-left:0;mso-wrap-distance-right:0;
   mso-position-horizontal-relative:text;mso-position-vertical-relative:text'
   coordsize="33655,7620" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Graphic_x0020_334" o:spid="_x0000_s1027" style='position:absolute;
    width:33655;height:7620;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="33655,7620" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m33527,l,,,7619r33527,l33527,xe" fillcolor="#5c2d91" stroked="f">
    <v:path arrowok="t"/>
   </v:shape></v:group><![endif]--><img width="3" height="1" src="file:///C:/Users/P20190~1/AppData/Local/Temp/msohtmlclip1/01/clip_image005.gif" /><u>Chest Pain*,</u> <u>Malaise*</u><u>,</u></p></td><td style="vertical-align:top"><p><u>Oedema</u> <u>Peripheral,</u> <u>Chills,</u> <u>Pyrexia*,</u> <u>Asthenia*,</u> <u>Thirst</u></p></td><td style="vertical-align:top"><p><u>Hernia, Drug</u> <u>Tolerance Decreased,</u> <u>Gait Disturbance</u></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><u>Very</u> <u>Common</u> </strong><u>(&ge;1/10)</u></p></td><td style="vertical-align:top"><p><strong><u>Common</u></strong></p><p><u>(&ge;1/100 to</u></p><p><u>&lt;1/10)</u></p></td><td style="vertical-align:top"><p><strong><u>Uncommon</u></strong></p><p><u>(&ge;1/1000 to</u></p><p><u>&lt;1/100)</u></p></td><td style="vertical-align:top"><p><strong><u>Rare</u></strong></p><p><u>(&ge;1/10000 to</u></p><p><u>&lt;1/1000)</u></p></td><td style="vertical-align:top"><p><strong><u>Very rare</u></strong></p><p><u>(&lt;1/10000)</u></p></td><td style="vertical-align:top"><p><strong><u>Frequency not</u> <u>Known</u> <u>(cannot be</u> <u>estimated from</u> <u>the available</u> <u>data)</u></strong></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em><u>Investigations</u></em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Alanine</u> <u>Aminotransfera</u> <u>rase Increased*,</u> <u>Aspartate</u> <u>Aminotransfera</u> <u>se Increased*,</u> <u>Weight</u> <u>Decreased*,</u> <u>Weight</u> <u>Increased*</u></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:group id="Group_x0020_339" o:spid="_x0000_s1026"
   style='position:absolute;left:0;text-align:left;margin-left:3.55pt;
   margin-top:36.85pt;width:3.15pt;height:.6pt;z-index:-18966528;
   mso-wrap-distance-left:0;mso-wrap-distance-right:0;
   mso-position-horizontal-relative:text;mso-position-vertical-relative:text'
   coordsize="40005,7620" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Graphic_x0020_340" o:spid="_x0000_s1027" style='position:absolute;
    width:40005;height:7620;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="40005,7620" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m39624,l,,,7620r39624,l39624,xe" fillcolor="#5c2d91" stroked="f">
    <v:path arrowok="t"/>
   </v:shape></v:group><![endif]--><img width="4" height="1" src="file:///C:/Users/P20190~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><u>Semen Abnormal,</u> <u>Blood cholesterol</u> <u>iIncreased</u></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Abnormal</u> <u>Clinical</u> <u>Laboratory</u> <u>Results, Altered</u> <u>Platelet</u> <u>Function</u></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em><u>Injury and poisoning</u></em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Injury</u></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em><u>Surgical and medical procedures</u></em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Vasodilation</u> <u>Procedure</u></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em><u>If adverse experience occurred in depression, OCD, panic disorder, PTSD and social anxiety disorder,</u> <u>body term reclassified by depression studies body term.</u></em></p><p><u>&dagger; <em>One case of neoplasm was reported in one patient receiving sertraline compared with no cases in</em></u><em> <u>the placebo arm.</u></em></p><p><em><u>* these adverse reactions also occurred in postmarketing experience</u></em></p><p><em><u>** the denominator uses the number of patients in that sex group-combined: sertraline (1118 males,</u> <u>1424 females) placebo (926 males, 1219 females)</u></em></p><p><em><u>For OCD, short term, 1-12 week studies only</u></em></p><p><em><u>*** Cases of suicidal ideation and suicidal behaviours have been reported during sertraline therapy or</u> <u>early after treatment discontinuation (see section 4.4).</u></em></p><p><u>&dagger; The event has been reported for the SSRI/SNRI therapeutic class (see sections 4.4 and 4.6).</u></p></td></tr></tbody></table><p><u>Withdrawal symptoms seen on discontinuation of sertraline&nbsp;</u><u>treatment</u></p><p>Discontinuation of sertraline&nbsp;(particularly when abrupt) commonly leads to withdrawal symptoms. Dizziness, sensory disturbances (including paraesthesia), sleep disturbances (including insomnia and intense dreams), agitation or anxiety, nausea and/or vomiting, tremor and headache are the most commonly reported. Generally these events are mild to moderate and are self-limiting; however, in some patients they may be severe and/or prolonged. It is therefore advised that when sertraline&nbsp;treatment is no longer required, gradual discontinuation by dose tapering should be carried out (see sections 4.2 and 4.4).</p><p><u>Elderly population</u></p><p>SSRIs or SNRIs including sertraline&nbsp;have been associated with cases of clinically significant hyponatraemia in elderly patients, who may be at greater risk for this adverse event (see section 4.4).</p><p><u>Paediatric population</u></p><p>In over 600 paediatric patients treated with sertraline, the overall profile of adverse reactions was generally similar to that seen in adult studies. The following adverse reactions were reported from controlled trials (n=281 patients treated with sertraline): Very common (&ge;1/10): Headache (22%), insomnia (21%), diarrhoea (11%) and nausea (15%). Common (&ge;1/100 to &lt;1/10): Chest pain, mania, pyrexia, vomiting, anorexia, affect lability, aggression, agitation, nervousness, disturbance in attention, dizziness, hyperkinesia, migraine, somnolence, tremor, visual disturbance, dry mouth, dyspepsia, nightmare, fatigue, urinary incontinence, rash, acne, epistaxis, flatulence. Uncommon (&ge;1/1000 to &lt;1/100): ECG QT prolonged (see sections 4.4, 4.5 and 5.1), suicide attempt, convulsion, extrapyramidal disorder, paraesthesia, depression, hallucination, purpura, hyperventilation, anaemia, hepatic function abnormal, alanine aminotransferase increased, cystitis, herpes simplex, otitis externa, ear pain, eye pain, mydriasis, malaise, haematuria, rash pustular,hinitis, injury, weight decreased, muscle twitching, abnormal dreams, apathy, albuminuria, pollakiuria, polyuria, breast pain, menstrual disorder, alopecia, dermatitis, skin disorder, skin odour abnormal, urticaria, bruxism, flushing. Frequency not known: enuresis</p><p><u>Class effects</u></p><p>Epidemiological studies, mainly conducted in patients 50 years of age and older, show an increased risk of bone fractures in patients receiving SSRIs and TCAs. The mechanism leading to this risk is unknown.</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after marketing authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions <u>according to their local country requirements.</u></p><p>To report any side effect(s):</p><p><strong>&bull; Saudi Arabia:</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p>The National Pharmacovigilance Centre (NPC):<br />SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p></td></tr></tbody></table><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><u>Other GCC States</u></strong></p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="Textbox_x0020_348" o:spid="_x0000_s1026" type="#_x0000_t202"
  style='position:absolute;margin-left:70.95pt;margin-top:13.2pt;width:354.45pt;
  height:13.2pt;z-index:-15615488;visibility:visible;mso-wrap-style:square;
  mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
  mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
  mso-position-horizontal-relative:page;mso-position-vertical:absolute;
  mso-position-vertical-relative:text;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" strokeweight=".48pt">
  <v:path arrowok="t"/>
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-left:13.4pt;line-height:12.6pt;
     mso-line-height-rule:exactly'><u style='text-underline:#D13438'><span
     style='color:#D13438'>-<span style='letter-spacing:3.0pt'> </span><i
     style='mso-bidi-font-style:normal'>Please<span style='letter-spacing:-.15pt'>
     </span>contact<span style='letter-spacing:-.05pt'> </span>the<span
     style='letter-spacing:-.1pt'> </span>relevant<span style='letter-spacing:
     -.2pt'> </span>competent<span style='letter-spacing:-.05pt'> </span><span
     style='letter-spacing:-.1pt'>authority.</span></i></span></u><i
     style='mso-bidi-font-style:normal'><o:p></o:p></i></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p>- <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Toxicity</u><br />Sertraline&nbsp;has a margin of safety dependent on patient population and/or concomitant medication. Deaths<br />have been reported involving overdoses of sertraline, alone or in combination with other drugs and/or<br />alcohol. Therefore, any overdosage should be medically treated aggressively.</p><p><u>Symptoms</u><br />Symptoms of overdose include serotonin-mediated side effects such as somnolence, gastrointestinal<br />disturbances (e.g. nausea and vomiting), tachycardia, tremor, agitation and dizziness. Coma has been<br />reported although less frequently.</p><p>QTc prolongation/Torsade de Pointes has been reported following sertraline overdose; therefore, ECGmonitoring<br />is recommended in all ingestions of sertraline overdoses (see sections 4.4, 4.5 and 5.1).</p><p><u>Management</u><br />There are no specific antidotes to sertraline. It is recommended to establish and maintain an airway and,<br />if necessary, ensure adequate oxygenation and ventilation. Activated charcoal, which may be used<br />with a cathartic, may be as, or more effective than lavage, and should be considered in treating<br />overdose. Induction of emesis is not recommended. Cardiac (e.g. ECG) and vital sign monitoring is<br />also recommended, along with general symptomatic and supportive measures. Due to the large volume<br />of distribution of sertraline, forced diuresis, dialysis, haemoperfusion and exchange transfusion are<br />unlikely to be of benefit.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Selective serotonin reuptake inhibitors (SSRI), ATC code: N06 AB06<br /><u>Mechanism of action</u></p><p>Sertraline&nbsp;is a potent and specific inhibitor of neuronal serotonin (5 HT) uptake in vitro, which results in<br />the potentiation of the effects of 5-HT in animals. It has only very weak effects on norepinephrine and<br />dopamine neuronal reuptake. At clinical doses, sertraline blocks the uptake of serotonin into human<br />platelets. It is devoid of stimulant, sedative or anticholinergic activity or cardiotoxicity in animals. In<br />controlled studies in normal volunteers, sertraline did not cause sedation and did not interfere with<br />psychomotor performance. In accord with its selective inhibition of 5-HT uptake, sertraline does not<br />enhance catecholaminergic activity. Sertraline has no affinity for muscarinic (cholinergic), serotonergic,<br />dopaminergic, adrenergic, histaminergic, GABA or benzodiazepine receptors. The chronic<br />administration of sertraline in animals was associated with down-regulation of brain norepinephrine<br />receptors as observed with other clinically effective antidepressants and antiobsessional drugs.<br />Sertraline&nbsp;has not demonstrated potential for abuse. In a placebo-controlled, double-blind randomized<br />study of the comparative abuse liability of sertraline, alprazolam and d-amphetamine in humans, sertraline<br />did not produce positive subjective effects indicative of abuse potential. In contrast, subjects rated both<br />alprazolam and d-amphetamine significantly greater than placebo on measures of drug liking, euphoria<br />and abuse potential. Lustral did not produce either the stimulation and anxiety associated with damphetamine<br />or the sedation and psychomotor impairment associated with alprazolam. Sertraline does<br />not function as a positive reinforcer in rhesus monkeys trained to self administer cocaine, nor does it<br />substitute as a discriminative stimulus for either d-amphetamine or pentobarbital in rhesus monkeys.</p><p><u>Clinical efficacy and safety</u></p><p><em><u>Major Depressive Disorder</u></em><br />A study was conducted which involved depressed outpatients who had responded by the end of an<br />initial 8-week open treatment phase on sertraline 50-200 mg/day. These patients (n=295) were<br />randomized to continuation for 44 weeks on double-blind sertraline 50-200 mg/day or placebo. A<br />statistically significantly lower relapse rate was observed for patients taking sertraline compared to those<br />on placebo. The mean dose for completers was 70 mg/day. The % of responders (defined as those<br />patients that did not relapse) for sertraline and placebo arms were 83.4% and 60.8%, respectively.</p><p><em><u>Post traumatic stress disorder (PTSD)</u></em><br />Combined data from the 3 studies of PTSD in the general population found a lower response rate in<br />males compared to females. In the two positive general population trials, the male and female sertraline<br />vs. placebo responder rates were similar (females: 57.2% vs 34.5%; males: 53.9% vs 38.2%). The<br />number of male and female patients in the pooled general population trials was 184 and 430,<br />respectively and hence the results in females are more robust and males were associated with other<br />baseline variables (more substance abuse, longer duration, source of trauma etc) which are correlated<br />with decreased effect.</p><p><em><u>Cardiac Electrophysiology</u></em><br />In a dedicated thorough QTc study, conducted at steady state at supratherapeutic exposures in healthy<br />volunteers (treated with 400 mg/day, twice the maximum recommended daily dose), the upper bound<br />of the 2-sided 90% CI for the time matched Least Square mean difference of QTcF between sertraline<br />and placebo (11.666 msec) was greater than the predefined threshold of 10 msec at the 4-hour<br />postdose time point. Exposure-response analysis indicated a slightly positive relationship between<br />QTcF and sertraline plasma concentrations [0.036 msec/(ng/mL); p&lt;0.0001]. Based on the exposure<br />response model, the threshold for clinically significant prolongation of the QTcF (i.e. for predicted<br />90% CI to exceed 10 msec) is at least 2.6-fold greater than the average Cmax (86 ng/mL) following<br />the highest recommended dose of sertraline (200 mg/day) (see sections 4.4, 4.5, 4.8 and 4.9).</p><p><em><u>Paediatric OCD</u></em><br />The safety and efficacy of sertraline (50-200 mg/day) was examined in the treatment of non-depressed<br />children (6-12 years old) and adolescent (13-17 years old) outpatients with obsessive compulsive<br />disorder (OCD). After a one week single blind placebo lead-in, patients were randomly assigned to<br />twelve weeks of flexible dose treatment with either sertraline or placebo. Children (6-12 years old) were</p><p>initially started on a 25 mg dose. Patients randomized to sertraline showed significantly greater<br />improvement than those randomised to placebo on the Children&rsquo;s Yale-Brown Obsessive Compulsive<br />Scale CY-BOCS (p =0.005) the NIMH Global Obsessive Compulsive Scale (p=0.019), and the CGI<br />Improvement (p =0.002) scales. In addition, a trend toward greater improvement in the sertraline group<br />than the placebo group was also observed on the CGI Severity scale (p=0.089). For CY-BOCs the<br />mean baseline and change from baseline scores for the placebo group was 22.25  6.15<br />and -3.4  0.82, respectively, while for the sertraline group, the mean baseline and change from baseline<br />scores were 23.36  4.56 and -6.8  0.87, respectively. In a post-hoc analysis, responders, defined as<br />patients with a 25% or greater decrease in the CY-BOCs (the primary efficacy measure) from baseline<br />to endpoint, were 53% of sertraline-treated patients compared to 37% of placebo-treated patients<br />(p=0.03).<br />Long term safety and efficacy data are lacking for this paediatric population.</p><p><u>Paediatric population</u><br />No data is available for children under 6 years of age.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u><br />In man, following an oral once-daily dosage of 50 to 200 mg for 14 days, peak plasma concentrations<br />of sertraline occur at 4.5 to 8.4 hours after the daily administration of the drug. Food does not<br />significantly change the bioavailability of sertraline tablets.</p><p><u>Distribution</u><br />Approximately 98% of the circulating drug is bound to plasma proteins.</p><p><u>Biotransformation</u><br />Sertraline&nbsp;undergoes extensive first-pass hepatic metabolism.<br />Based on clinical and in-vitro data, it can be concluded that sertraline is metabolized by multiple<br />pathways including CYP3A4, CYP2C19 (see section 4.5) and CYP2B6. Sertraline and its major<br />metabolite desmethylsertraline are also substrate of P-glycoprotein in-vitro.</p><p><u>Elimination</u><br />The mean half-life of sertraline is approximately 26 hours (range 22-36 hours). Consistent with the<br />terminal elimination half-life, there is an approximately two-fold accumulation up to steady state<br />concentrations, which are achieved after one week of once-daily dosing. The half-life of<br />N-desmethylsertraline is in the range of 62 to 104 hours. Sertraline and N-desmethylsertraline are both<br />extensively metabolized in man and the resultant metabolites excreted in faeces and urine in equal<br />amounts. Only a small amount (&lt;0.2%) of unchanged sertraline is excreted in the urine.</p><p><u>Linearity/non-linearity</u><br />Sertraline&nbsp;exhibits dose proportional pharmacokinetics in the range of 50 to 200 mg.</p><p><em><u>Pharmacokinetics in specific patient groups</u></em></p><p><em><u>Paediatric population with OCD</u></em><br />Pharmacokinetics of sertraline was studied in 29 paediatric patients aged 6-12 years old, and 32<br />adolescent patients aged 13-17 years old. Patients were gradual uptitrated to a 200 mg daily dose<br />within 32 days, either with 25 mg starting dose and increment steps, or with 50 mg starting dose or<br />increments. The 25 mg regimen and the 50 mg regimen were equally tolerated. In steady state for the<br />200 mg dose, the sertraline plasma levels in the 6-12 year old group were approximately 35% higher<br />compared to the 13-17 year old group, and 21% higher compared to adult reference group. There were<br />no significant differences between boys and girls regarding clearance. A low starting dose and titration</p><p>steps of 25 mg are therefore recommended for children, especially with low bodyweight. Adolescents<br />could be dosed like adults.</p><p><em><u>Adolescents and elderly</u></em><br />The pharmacokinetic profile in adolescents or elderly is not significantly different from that in adults<br />between 18 and 65 years.</p><p><em><u>Hepatic impairment</u></em><br />In patients with liver damage, the half life of sertraline is prolonged and AUC is increased three fold (see<br />sections 4.2 and 4.4).</p><p><em><u>Renal impairment</u></em><br />In patients with moderate-severe renal impairment, there was no significant accumulation of sertraline.</p><p><em><u>Pharmacogenomics</u></em><br />Plasma levels of sertraline were about 50% higher in poor metabolizers of CYP2C19 versus extensive<br />metabolizers. The clinical meaning is not clear, and patients need to be titrated based on clinical<br />response.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data does not indicate any special hazard for humans based on conventional studies of<br />safety pharmacology, repeated dose toxicity, genotoxicity and carcinogenesis. Reproduction toxicity<br />studies in animals showed no evidence of teratogenicity or adverse effects on male fertility. Observed<br />foetotoxicity was probably related to maternal toxicity. Postnatal pup survival and body weight were<br />decreased only during the first days after birth. Evidence was found that the early postnatal mortality<br />was due to in-utero exposure after day 15 of pregnancy. Postnatal developmental delays found in pups<br />from treated dams were probably due to effects on the dams and therefore not relevant for human risk.</p><p>Animal data from rodents and non-rodents does not reveal effects on fertility.</p><p><em>Juvenile animal studies</em></p><p>A juvenile toxicology study in rats has been conducted in which sertraline was administered orally to<br />male and female rats on Postnatal Days 21 through 56 (at doses of 10, 40, or 80 mg/kg/day) with a<br />nondosing recovery phase up to Postnatal Day 196. Delays in sexual maturation occurred in males and<br />females at different dose levels (males at 80 mg/kg and females at &ge;10 mg/kg), but despite this finding<br />there were no sertraline-related effects on any of the male or female reproductive endpoints that were<br />assessed. In addition, on Postnatal Days 21 to 56, dehydration, chromorhinorrhea, and reduced average<br />body weight gain was also observed. All of the aforementioned effects attributed to the administration<br />of sertraline were reversed at some point during the nondosing recovery phase of the study. The clinical<br />relevance of these effects observed in rats administered sertraline has not been established.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lustral film-coated tablets:<br /><em>Tablet cores:</em><br />calcium hydrogen phosphate dihydrate (E341)<br />microcrystalline cellulose (E460)<br />hydroxypropylcellulose (E463)</p><p>sodium starch glycollate (Type A)<br />magnesium stearate (E572)<br /><em>Film coating:</em><br />Opadry White containing:<br />titanium dioxide (E171)<br />hypromellose 2910, 3 cP&nbsp;(E464)<br />hypromellose 2910, cP&nbsp;(E464)<br />macrogol 400 (E1521)<br />polysorbate 80 (E433)<br /><em>Opadry Clear containing:</em><br />hypromellose 2910, 6 cP&nbsp; (E464)<br />macrogol 400 (E1521)<br />macrogol&nbsp; 6000 (E1521)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Do not use LUSTRAL after the expiry date which is stated on the Carton label after EXP:. The expiry
date refers to the last day of that month.
Shelf life: 36 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below30&deg; C.</p><p>Keep out of the sight and reach of children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lustral 50 mg film-coated tablets:&nbsp;</p><p>Tablets are packed in Aluminium/PVC blisters of 30 tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SPIMACO
Al-Qassim Pharmaceutical Plant, Saudi Arabia.
Under licence from Viatris.
MANUFACTURED BY:
SPIMACO
Al-Qassim Pharmaceutical Plant, Saudi Arabia.
Under licence from Viatris.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                December 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>